tailoring treatment for metastatic colorectal cancer · tailoring treatment for metastatic...

54
OptimizingTreatmentStrategiesin Colorectal Cancer Tailoring treatment for metastatic colorectal cancer Considerations for first-line therapy Edward Lin, MD Associate Professor, University of Washington Associate Member, Fred Hutchinson Cancer Research Center Seattle, Washington Edith Mitchell, MD Clinical Professor of Medicine and Medical Oncology Gastrointestinal Oncology, Thomas Jefferson University Philadelphia, Pennsylvania Pfizer Oncology Presents

Upload: others

Post on 05-Jun-2020

12 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

�Optimizing�Treatment�Strategies�in

Colorectal Cancer

Tailoring treatment for metastatic colorectal cancerConsiderations for first-line therapy

Edward Lin, MD Associate Professor, University of Washington Associate Member, Fred Hutchinson Cancer Research Center Seattle, Washington

Edith Mitchell, MD Clinical Professor of Medicine and Medical Oncology Gastrointestinal Oncology, Thomas Jefferson University Philadelphia, Pennsylvania

Pfizer Oncology Presents

Page 2: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer
Page 3: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

�Optimizing�Treatment�Strategies�in

Colorectal Cancer

Tailoring treatment for metastatic colorectal cancerConsiderations for first-line therapy

Edward Lin, MD Associate Professor, University of Washington Associate Member, Fred Hutchinson Cancer Research Center Seattle, Washington

Edith Mitchell, MD Clinical Professor of Medicine and Medical Oncology Gastrointestinal Oncology, Thomas Jefferson University Philadelphia, Pennsylvania

Pfizer Oncology Presents

Editorial support and publishing was provided by Current Medicine Group LLC and funded by Pfizer Inc.

Page 4: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy

Key Points• Colorectal cancer (CRC) will affect an estimated 153,760 people in the USA in

2007; a third of these patients will die from metastatic disease.

• Treatment strategies need to be tailored to the defined goal of treatment and tumor presentation.

• The goal of therapy needs to be defined upfront with the patient and therapy reassessed as treatment evolves.

• More than one regimen is recognized as a standard approach to treating advanced metastatic disease.

• For patients who can tolerate intensive therapy, two primary options recommended by the National Comprehensive Cancer Network® (NCCN) guidelines for initial therapy are FOLFIRI and FOLFOX; different factors may influence the choice.

• Integration of multimodality therapy, including surgery and radiation, may be necessary.

IntroductionThe annual incidence of new cases of CRC is approximately 150,000 in the USA alone (Figure 1), with about a third of these patients expected to die as a result of metastatic colorectal cancer (mCRC).1

Please see the full CAMPTOSAR® (irinotecan HCl) prescribing information on pages 8 to 13.

Figure 1. Estimated new colorectal cancer cases and deaths in the USA in 20071

For many years, 5-fluorouracil (5-FU) has been available for treating patients with colorectal cancer and remains the backbone of mCRC treatment, even with the introduction of irinotecan,2 oxaliplatin,3 capecitabine,4 bevacizumab,5 cetuximab,6 and more recently, panitumumab.7

Combining continuous infusion 5-FU with either irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) is now the de facto first-line standard for the treatment of advanced CRC, resulting in a median overall survival of almost 2 years.8–11 Although FOLFOX is used more frequently

Page 5: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

as first-line therapy, data show that FOLFIRI is equally effective.8–12 Further consideration for adding a targeted agent, such as bevacizumab, may be appropriate as indicated in the NCCN guidelines.13

Given the proven effectiveness of several regimens, an increasing number of patients now receive multiple lines of therapy. Considering the heterogeneous nature of tumor presentations, and the many parallel treatment options set out by the NCCN guidelines,13 the goals of this bulletin are to help clinicians:

• Better understand how to tailor treatment strategies to the individual needs of patients;

• Recognize the need, based on the disease characteristics and the patient’s needs, to consider more than one regimen as the standard approach to treating mCRC.

Tenets of tailored therapyGiven the significant heterogeneity of mCRC and the many therapeutic options, treatment decisions should consider the following:

1. Define and redefine the goal of therapy;

2. Assess disease patterns and comorbidities;

3. Discuss treatment options, including clinical trials, with patients;

4. Manage and reduce toxicity;

5. Integrate a multimodality therapy, including surgery and radiation.

Define and redefine the goal of therapy

The first step in treating a patient with CRC is to determine the extent of involvement of distant organs and to determine the goal of therapy with the patient. For the group of patients who present with extensive, unresectable metastases, the goal of therapy would be largely palliative. Therefore, the therapeutic decision should focus on extending survival with an optimal sequence of therapeutic agents and on quality of life by reducing treatment-related toxicities.

On the other hand, if the disease can be treated with locoregional therapy such as surgery, an ablative technique, or radiation therapy, the goal may be to render the patient free of visible disease to achieve long-term remission or cure. Throughout the management process, it is important to redefine the goals of therapy with the patient.

Assess disease patterns and comorbidities

The next step toward tailored treatment is to evaluate other disease processes that could potentially have an impact on the effectiveness of treatment. For those patients with extensive multivisceral metastases, the chosen therapy should take into account the response rate, toxicity profiles, and the subsequent planned care that may allow the optimal exposure to the therapeutic agents.

Please see the full CAMPTOSAR® (irinotecan HCl) prescribing information on pages 8 to 13.

Page 6: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Preexisting medical conditions, for example, may shape the use of some therapies and limit the administration of others. The chosen therapy should be tailored based on the patients’ comorbidities and stated goal, taking into account the toxicity profiles of the therapeutic agents and a full understanding of their relative contraindications.

Discuss treatment options

It is important to thoroughly discuss all of the available treatment options with patients and evaluate each individual’s needs. While it is ideal to enroll patients into well-designed clinical trials, unfortunately this is not a viable option for all patients. Deciding which regimen to use first-line will be influenced not only by whether or not the patients can tolerate effective, intensive chemotherapy but also if they are willing to.13

FOLFIRI and FOLFOX are both proven effective for first-line treatment. In a Tournigand et al phase 3 sequencing study of first-line FOLFIRI followed by second-line FOLFOX or the reverse, there were equivalent first-line response rates and median overall survival.8 In terms of safety, no significant difference was shown between FOLFOX and FOLFIRI in grade 3 or 4 diarrhea. The FOLFIRI arm was associated with more grade 3 or 4 febrile neutropenia, nausea and vomiting, mucositis, and fatigue. The FOLFOX arm was associated with more grade 3 sensory neurotoxicity, grade 3 or 4 neutropenia, and thrombocytopenia.8

FOLFOX is an effective first-line treatment option to be discussed. The most common oxaliplatin-associated adverse events are peripheral sensory neuropathies, fatigue, neutropenia, nausea, emesis, and diarrhea.14 Many practitioners are now facing the challenges of managing grade 2 or 3 cumulative peripheral neurotoxicity that can frequently occur in patients exposed to oxaliplatin as part of the FOLFOX regimen. Neurotoxicities can present as initially subtle, such as difficulty in buttoning a shirt, and may become as severe as full gait disturbances with prolonged use of oxaliplatin. It is, therefore, important to discuss with patients the potential neurotoxicity of oxaliplatin.

FOLFIRI is also an effective first-line treatment choice to be discussed. The most common irinotecan-associated adverse events are diarrhea, neutropenia, emesis, and nausea.15 Irinotecan is associated with both early and late forms of diarrhea, which may be severe. Early diarrhea occurs during or shortly after infusion. It may be accompanied by cholinergic symptoms. Late diarrhea generally occurs more than 24 hours after administration. Both forms can be life threatening. Therefore, it is important to discuss the risks with patients, and all attempts should be made to manage such an event.

Appropriate considerations should be given to adding bevacizumab as per NCCN guidelines.13 As with other active agents, bevacizumab is associated with adverse events, which need to be considered when treating patients. Among these are grade 3 or 4 hypertension, diarrhea, and leukopenia.9 Furthermore, treatment with bevacizumab should be delayed for at least two half-lives (ie, 8 weeks) if there is a need for any surgical intervention to minimize fistula or wound dehiscence risk.16

Other potential considerations when deciding first-line treatment are the patient’s age, performance status, and underlying genetic polymorphisms. Studies continue to investigate the role of microsatellite instability as a predictive marker, and further research is looking at ethnicity and the impact of DNA polymorphisms on levels of response.

Please see the full CAMPTOSAR® (irinotecan HCl) prescribing information on pages 8 to 13.

Page 7: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Manage and reduce toxicity

In a palliative setting, overall toxicities and quality of life have become the number one priority of treatment. Because toxicities are an important part of selecting both the initial first-line treatment and subsequent therapies, research that evaluates strategies to decrease and manage potential acute and cumulative toxicities is critical. Investigational approaches to limit the toxicity associated with certain therapies17,18 may help to enhance patients’ tolerance of therapy in the future.

Once therapy is initiated, three guiding tenets can help to drive ongoing therapeutic decisions.

1. Continue an effective therapy as long as possible and institute appropriate treatment breaks due to adverse events.

2. Discontinue ineffective or toxic chemotherapy regimens as early as possible to explore other parallel therapeutic options.

3. Provide early and optimal integration of multimodal therapy such as surgery and possibly also radiotherapy for potential “cure” when this is feasible.

Strategic approaches to further reduce toxicity include assessing patient experience on prior treatments. For example, adverse events experienced during prior adjuvant treatment is one factor that should be considered when selecting first-line treatment. In some instances, for patients previously treated with FOLFOX adjuvant, physicians may consider a different regimen – such as FOLFIRI – in first-line mCRC, if a patient previously developed cumulative neuropathy with FOLFOX. Other clinical management approaches may involve consideration of whether a “stop and go” strategy has been used before to mitigate cumulative toxicities.18

For patients who have progressed, the need to manage toxicity continues. Following progression in first-line, there are several therapeutic options available, such as the use of cetuximab with irinotecan for patients who have become refractory to irinotecan. Recognizing and then minimizing the occurrence of cetuximab- or panitumumab-induced skin toxicities and hypomagnesemia is the key to the therapy continuum of advanced CRC. Use of palliative radiation should also be considered.

Integrate a multimodality therapy, including surgery and radiation

Recognizing or selecting mCRC patients according to tumor biology (eg, long disease-free interval, solitary metastasis, carcinoembryonic antigen <200 ng/mL) ensures the best surgical outcome and may limit the role of adjuvant chemotherapy. Selective use of targeted curative radiation may have the same merits as surgical resection.19

It should be borne in mind that for those patients with resectable liver metastases on presentation, or those who are rendered operable by chemotherapy, there are eight unique segmental hepatic blood supplies and surgical techniques (eg, left or right hepatectomy, segmentectomy, extended left or right hepatectomy) that may be of benefit.20

Please see the full CAMPTOSAR® (irinotecan HCl) prescribing information on pages 8 to 13.

Page 8: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

ConclusionAlthough CRC remains a clinical challenge, selecting the most effective treatment for individual patients requires taking into consideration multiple tenets. As clinicians, these new regimens provide us with opportunities not only to tailor treatment to the individual patient’s needs, but also to take into consideration the patient’s overall quality of life.

Important information (CAMPTOSAR)

CAMPTOSAR® (irinotecan HCl) is indicated as a component of first-line therapy in combination with 5-FU/LV for the treatment of mCRC. CAMPTOSAR is also indicated in the treatment of patients with mCRC, whose disease has recurred or progressed following initial FU-based therapy.

Both early and late forms of diarrhea can occur and may be life threatening. Late diarrhea should be managed promptly with loperamide and supportive care including antibiotics as needed.

CAMPTOSAR can induce severe myelosuppression. Depending on the severity of neutropenia, dose delay, dose reduction or use of a colony-stimulating factor should be considered.

Particular caution should be exercised in monitoring the effects of CAMPTOSAR in the elderly (>65), in patients who have previously received pelvic/abdominal irradiation, in patients with a performance status of 2 or higher, and in patients known to be homozygous for the UGT1A1*28 allele. Rare cases of ileus, complicated colitis, or renal impairment have been observed. It is recommended that patients receive premedication with antiemetic agents. Prophylactic or therapeutic administration of atropine should be considered in patients experiencing cholinergic symptoms. Provided intolerable toxicity does not develop, treatment with additional courses may be continued indefinitely as long as patients continue to experience clinical benefits. Thromboembolic events have been observed but the specific cause has not been determined. CAMPTOSAR should not be used in patients with severe bone marrow failure. In addition, patients with hereditary fructose intolerance should not be given CAMPTOSAR, as this product contains sorbitol.

Please see the full CAMPTOSAR® (irinotecan HCl) prescribing information on pages 8 to 13.

Page 9: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

1 Jemal A, Siegel R, Ward E, et al. Cancer statis-tics, 2007. CA Cancer J Clin 2007;57(1):43–66.

2 Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 2006;32(7):491–503.

3 Simpson D, Dunn C, Curran M, Goa KL. Oxali-platin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 2003;63(19):2127–2156.

4 Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006;107(2):221–231.

5 Hurwitz H, Kabbinavar F. Bevacizumab com-bined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology 2005;69(Suppl 3):17–24.

6 Cerea G, Ricotta R, Schiavetto I, et al. Cetuxi-mab for treatment of metastatic colorectal cancer. Ann Oncol 2006;17(Suppl 7):vii66–vii67.

7 Wainberg Z, Hecht JR. Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin Biol Ther 2006;6(11):1229–1235.

8 Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2): 229–237.

9 Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335–2342.

10 Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer corre-lates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23(36):9441–9442.

11 Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combi-

nations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23–30.

12 Colucci G, Gebbia V, Paoletti G, et al; Gruppo Oncologico Dell’Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colo-rectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23(22):4866–4875.

13 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncol-ogy Version 1. 2007: Colon Cancer. Available at: www.nccn.org/professionals/physician_gls/PDF/colon.pdf. Accessed April 18, 2007.

14 Eloxatin (US prescribing information). Bridge- water, NJ: sanofi-aventis US LLC; 2006.

15 Camptosar (US prescribing information). New York, NY: Pfizer Inc; 2006.

16 Avastin (US prescribing information). South San Francisco, CA: Genentech Inc; 2006.

17 Highlights from the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Clin Colorectal Cancer 2006;5: 398–402.

18 Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol 2006;24(3): 394–400.

19 Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resec-tion for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230(3): 309-318.

20 Herbert R, McCollum VT, Cassidy A, et al. Imaging of the liver prior to hepatic resection: basic anatomical considerations. Radiography 2003; 9(1):53–62.

Please see the full CAMPTOSAR® (irinotecan HCl) prescribing information on pages 8 to 13.

References �

Page 10: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

WARNINGSCAMPTOSAR Injection should be administered only under the supervision

of a physician who is experienced in the use of cancer chemotherapeuticagents. Appropriate management of complications is possible only whenadequate diagnostic and treatment facilities are readily available. CAMPTOSAR can induce both early and late forms of diarrhea that appear tobe mediated by different mechanisms. Both forms of diarrhea may be severe.Early diarrhea (occurring during or shortly after infusion of CAMPTOSAR)may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperi-stalsis that can cause abdominal cramping. Early diarrhea and other cholinergic symptoms may be prevented or ameliorated by atropine (seePRECAUTIONS, General). Late diarrhea (generally occurring more than 24hours after administration of CAMPTOSAR) can be life threatening since itmay be prolonged and may lead to dehydration, electrolyte imbalance, orsepsis. Late diarrhea should be treated promptly with loperamide. Patientswith diarrhea should be carefully monitored and given fluid and electrolytereplacement if they become dehydrated or antibiotic therapy if they developileus, fever, or severe neutropenia (see WARNINGS). Administration ofCAMPTOSAR should be interrupted and subsequent doses reduced if severediarrhea occurs (see DOSAGE AND ADMINISTRATION).

Severe myelosuppression may occur (see WARNINGS).

DESCRIPTIONCAMPTOSAR Injection (irinotecan hydrochloride injection) is an antineo-

plastic agent of the topoisomerase I inhibitor class. Irinotecan hydrochloride wasclinically investigated as CPT-11.

CAMPTOSAR is supplied as a sterile, pale yellow, clear, aqueous solution. It isavailable in two single-dose sizes: 2 mL-fill vials contain 40 mg irinotecanhydrochloride and 5 mL-fill vials contain 100 mg irinotecan hydrochloride. Eachmilliliter of solution contains 20 mg of irinotecan hydrochloride (on the basis ofthe trihydrate salt), 45 mg of sorbitol NF powder, and 0.9 mg of lactic acid, USP.The pH of the solution has been adjusted to 3.5 (range, 3.0 to 3.8) with sodiumhydroxide or hydrochloric acid. CAMPTOSAR is intended for dilution with 5%Dextrose Injection, USP (D5W), or 0.9% Sodium Chloride Injection, USP, prior tointravenous infusion. The preferred diluent is 5% Dextrose Injection, USP.

Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, analkaloid extract from plants such as Camptotheca acuminata or is chemically syn-thesized. The chemical name is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano[3’,4’:6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4’bipiperidine]-1’-carboxylate, monohydrochloride, trihydrate. Its structural formula is asfollows:

Irinotecan HydrochlorideIrinotecan hydrochloride is a pale yellow to yellow crystalline powder, with the

empirical formula C33H38N4O6•HCl•3H2O and a molecular weight of 677.19. It isslightly soluble in water and organic solvents.

CLINICAL PHARMACOLOGYIrinotecan is a derivative of camptothecin. Camptothecins interact specifically

with the enzyme topoisomerase I which relieves torsional strain in DNA by induc-ing reversible single-strand breaks. Irinotecan and its active metabolite SN-38bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is dueto double-strand DNA damage produced during DNA synthesis when replicationenzymes interact with the ternary complex formed by topoisomerase I, DNA, andeither irinotecan or SN-38. Mammalian cells cannot efficiently repair thesedouble-strand breaks.

Irinotecan serves as a water-soluble precursor of the lipophilic metabolite SN-38. SN-38 is formed from irinotecan by carboxylesterase-mediated cleavage of thecarbamate bond between the camptothecin moiety and the dipiperidino sidechain. SN-38 is approximately 1000 times as potent as irinotecan as an inhibitorof topoisomerase I purified from human and rodent tumor cell lines. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan variesfrom 2- to 2000-fold. However, the plasma area under the concentration versustime curve (AUC) values for SN-38 are 2% to 8% of irinotecan and SN-38 is 95%bound to plasma proteins compared to approximately 50% bound to plasma pro-teins for irinotecan (see Pharmacokinetics). The precise contribution of SN-38 tothe activity of CAMPTOSAR is thus unknown. Both irinotecan and SN-38 exist inan active lactone form and an inactive hydroxy acid anion form. A pH-dependentequilibrium exists between the two forms such that an acid pH promotes the for-mation of the lactone, while a more basic pH favors the hydroxy acid anion form.

Administration of irinotecan has resulted in antitumor activity in mice bearing cancers of rodent origin and in human carcinoma xenografts of varioushistological types.Pharmacokinetics

After intravenous infusion of irinotecan in humans, irinotecan plasma concen-trations decline in a multiexponential manner, with a mean terminal eliminationhalf-life of about 6 to 12 hours. The mean terminal elimination half-life of theactive metabolite SN-38 is about 10 to 20 hours. The half-lives of the lactone(active) forms of irinotecan and SN-38 are similar to those of total irinotecan andSN-38, as the lactone and hydroxy acid forms are in equilibrium.

Over the recommended dose range of 50 to 350 mg/m2, the AUC of irinotecan increases linearly with dose; the AUC of SN-38 increases less than pro-portionally with dose. Maximum concentrations of the active metabolite SN-38are generally seen within 1 hour following the end of a 90-minute infusion ofirinotecan. Pharmacokinetic parameters for irinotecan and SN-38 following a 90-minute infusion of irinotecan at dose levels of 125 and 340 mg/m2 determinedin two clinical studies in patients with solid tumors are summarized in Table 1:

Table 1. Summary of Mean (±Standard Deviation)Irinotecan and SN-38 Pharmacokinetic

Parameters in Patients with Solid TumorsIrinotecan SN-38

Dose(mg/m2) Cmax AUC0-24 t1/2 Vz CL Cmax AUC0-24 t1/2

(ng/mL) (ng·h/mL) (h) (L/m2) (L/h/m2) (ng/mL)(ng·h/mL) (h)

125 1,660 10,200 5.8a 110 13.3 26.3 229 10.4a

(N=64) ±797 ±3,270 ±0.7 ±48.5 ±6.01 ±11.9 ±108 ±3.1

340 3,392 20,604 11.7b 234 13.9 56.0 474 21.0b

(N=6) ±874 ±6,027 ±1.0 ±69.6 ±4.0 ±28.2 ±245 ±4.3

Cmax - Maximum plasma concentrationAUC0-24 - Area under the plasma concentration-time curve from time 0 to 24

hours after the end of the 90-minute infusiont1/2 - Terminal elimination half-lifeVz - Volume of distribution of terminal elimination phaseCL - Total systemic clearancea Plasma specimens collected for 24 hours following the end of the 90-minute

infusion.b Plasma specimens collected for 48 hours following the end of the 90-minute

infusion. Because of the longer collection period, these values provide a more accurate reflection of the terminal elimination half-lives of irinotecan andSN-38.

Irinotecan exhibits moderate plasma protein binding (30% to 68% bound). SN-38 is highly bound to human plasma proteins (approximately 95%bound). The plasma protein to which irinotecan and SN-38 predominantly bindsis albumin.Metabolism and Excretion: The metabolic conversion of irinotecan to the activemetabolite SN-38 is mediated by carboxylesterase enzymes and primarily occursin the liver. SN-38 is subsequently conjugated predominantly by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite.UGT1A1 activity is reduced in individuals with genetic polymorphisms that leadto reduced enzyme activity such as the UGT1A1*28 polymorphism.Approximately 10% of the North American population is homozygous for theUGT1A1*28 allele. In a prospective study, in which irinotecan was administeredas a single-agent on a once-every-3-week schedule, patients who were homozygous for UGT1A1*28 had a higher exposure to SN-38 than patients withthe wild-type UGT1A1 allele (See WARNINGS and DOSAGE AND ADMINISTRA-TION). SN-38 glucuronide had 1/50 to 1/100 the activity of SN-38 in cytotoxicityassays using two cell lines in vitro. The disposition of irinotecan has not been fullyelucidated in humans. The urinary excretion of irinotecan is 11% to 20%; SN-38,<1%; and SN-38 glucuronide, 3%. The cumulative biliary and urinary excretionof irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of48 hours following administration of irinotecan in two patients ranged fromapproximately 25% (100 mg/m2) to 50% (300 mg/m2).Pharmacokinetics in Special PopulationsGeriatric: In studies using the weekly schedule, the terminal half-life of irinotecanwas 6.0 hours in patients who were 65 years or older and 5.5 hours in patientsyounger than 65 years. Dose-normalized AUC0-24 for SN-38 in patients who wereat least 65 years of age was 11% higher than in patients younger than 65 years.No change in the starting dose is recommended for geriatric patients receivingthe weekly dosage schedule of irinotecan. The pharmacokinetics of irinotecangiven once every 3 weeks has not been studied in the geriatric population; a lowerstarting dose is recommended in patients 70 years or older based on clinical tox-icity experience with this schedule (see DOSAGE AND ADMINISTRATION).Pediatric: See Pediatric Use under PRECAUTIONS.Gender: The pharmacokinetics of irinotecan do not appear to be influenced bygender.Race: The influence of race on the pharmacokinetics of irinotecan has not beenevaluated.Hepatic Insufficiency: Irinotecan clearance is diminished in patients with hepaticdysfunction while exposure to the active metabolite SN-38 is increased relative tothat in patients with normal hepatic function. The magnitude of these effects isproportional to the degree of liver impairment as measured by elevations in totalbilirubin and transaminase concentrations. However, the tolerability of irinotecanin patients with hepatic dysfunction (bilirubin greater than 2 mg/dl) has not beenassessed sufficiently, and no recommendations for dosing can be made (seeDOSAGE AND ADMINISTRATION and PRECAUTIONS: Patients at Particular RiskSections).Renal Insufficiency: The influence of renal insufficiency on the pharmacokineticsof irinotecan has not been evaluated. Therefore, caution should be undertaken inpatients with impaired renal function. Irinotecan is not recommended for use inpatients on dialysis.Drug-Drug Interactions

5-fluorouracil (5-FU) and leucovorin (LV): In a phase 1 clinical study involvingirinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solidtumors, the disposition of irinotecan was not substantially altered when the drugswere co-administered. Although the Cmax and AUC0-24 of SN-38, the activemetabolite, were reduced (by 14% and 8%, respectively) when irinotecan wasfollowed by 5-FU and LV administration compared with when irinotecan wasgiven alone, this sequence of administration was used in the combination trialsand is recommended (see DOSAGE AND ADMINISTRATION). Formal in vivo orin vitro drug interaction studies to evaluate the influence of irinotecan on the dis-position of 5-FU and LV have not been conducted.

Anticonvulsants: Exposure to irinotecan and its active metabolite SN-38 issubstantially reduced in adult and pediatric patients concomitantly receiving theCYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital or carba-mazepine. The appropriate starting dose for patients taking these anticonvulsantshas not been formally defined. The following drugs are also CYP3A4 inducers:rifampin, rifabutin. For patients requiring anticonvulsant treatment, considerationshould be given to substituting non-enzyme inducing anticonvulsants at least 2weeks prior to initiation of irinotecan therapy. Dexamethasone does not appear toalter the pharmacokinetics of irinotecan.

St. John’s Wort: St. John’s Wort is an inducer of CYP3A4 enzymes. Exposureto the active metabolite SN-38 is reduced in patients receiving concomitant St.John’s Wort. St. John’s Wort should be discontinued at least 2 weeks prior to thefirst cycle of irinotecan, and St. John’s Wort is contraindicated during irinotecantherapy.

Ketoconazole: Ketoconazole is a strong inhibitor of CYP3A4 enzymes. Patientsreceiving concomitant ketoconazole have increased exposure to irinotecan and itsactive metabolite SN-38. Patients should discontinue ketoconazole at least 1 weekprior to starting irinotecan therapy and ketoconazole is contraindicated duringirinotecan therapy.

Neuromuscular blocking agents. Interaction between irinotecan and neuromuscular blocking agents cannot be ruled out. Irinotecan has anti-cholinesterase activity, which may prolong the neuromuscular blocking effects ofsuxamethonium and the neuromuscular blockade of non-depolarizing drugs maybe antagonized.

Atazanavir sulfate: Coadministration of atazanavir sulfate, a CYP3A4 andUGT1A1 inhibitor has the potential to increase systemic exposure to SN-38, theactive metabolite of irinotecan. Physicians should take this into considerationwhen co-administering these drugs.

CLINICAL STUDIESIrinotecan has been studied in clinical trials in combination with 5-fluorouracil

(5-FU) and leucovorin (LV) and as a single agent (see DOSAGE AND ADMINIS-TRATION). When given as a component of combination-agent treatment, irinote-can was either given with a weekly schedule of bolus 5-FU/LV or with an every-2-week schedule of infusional 5-FU/LV. Weekly and a once-every-3-week dosageschedules were used for the single-agent irinotecan studies. Clinical studies ofcombination and single-agent use are described below.First-Line Therapy in Combination with 5-FU/LV for the Treatment of MetastaticColorectal Cancer

Two phase 3, randomized, controlled, multinational clinical trials support theuse of CAMPTOSAR Injection as first-line treatment of patients with metastaticcarcinoma of the colon or rectum. In each study, combinations of irinotecan with5-FU and LV were compared with 5-FU and LV alone. Study 1 compared combi-nation irinotecan/bolus 5-FU/LV therapy given weekly with a standard bolus reg-imen of 5-FU/LV alone given daily for 5 days every 4 weeks; an irinotecan-alonetreatment arm given on a weekly schedule was also included. Study 2 evaluatedtwo different methods of administering infusional 5-FU/LV, with or withoutirinotecan. In both studies, concomitant medications such as antiemetics,atropine, and loperamide were given to patients for prophylaxis and/or manage-ment of symptoms from treatment. In Study 2, a 7-day course of fluoroquinoloneantibiotic prophylaxis was given in patients whose diarrhea persisted for greaterthan 24 hours despite loperamide or if they developed a fever in addition to diar-rhea. Treatment with oral fluoroquinolone was also initiated in patients who devel-oped an absolute neutrophil count (ANC) <500/mm3, even in the absence of feveror diarrhea. Patients in both studies also received treatment with intravenousantibiotics if they had persistent diarrhea or fever or if ileus developed.

In both studies, the combination of irinotecan/5-FU/LV therapy resulted in significant improvements in objective tumor response rates, time to tumor pro-gression, and survival when compared with 5-FU/LV alone. These differences insurvival were observed in spite of second-line therapy in a majority of patients onboth arms, including crossover to irinotecan-containing regimens in the controlarm. Patient characteristics and major efficacy results are shown in Table 2.

Improvement was noted with irinotecan-based combination therapy relative to5-FU/LV when response rates and time to tumor progression were examinedacross the following demographic and disease-related subgroups (age, gender,ethnic origin, performance status, extent of organ involvement with cancer, timefrom diagnosis of cancer, prior adjuvant therapy, and baseline laboratory abnor-malities). Figures 1 and 2 illustrate the Kaplan-Meier survival curves for the com-parison of irinotecan/5-FU/LV versus 5-FU/LV in Studies 1 and 2, respectively.Second-Line Treatment for Recurrent or Progressive Metastatic ColorectalCancer After 5-FU-Based TreatmentWeekly Dosage Schedule

Data from three open-label, single-agent, clinical studies, involving a total of304 patients in 59 centers, support the use of CAMPTOSAR in the treatment ofpatients with metastatic cancer of the colon or rectum that has recurred or pro-gressed following treatment with 5-FU-based therapy. These studies weredesigned to evaluate tumor response rate and do not provide information onactual clinical benefit, such as effects on survival and disease-related symptoms.In each study, CAMPTOSAR was administered in repeated 6-week cycles consist-ing of a 90-minute intravenous infusion once weekly for 4 weeks, followed by a2-week rest period. Starting doses of CAMPTOSAR in these trials were 100, 125,or 150 mg/m2, but the 150-mg/m2 dose was poorly tolerated (due to unaccept-ably high rates of grade 4 late diarrhea and febrile neutropenia). Study 1 enrolled48 patients and was conducted by a single investigator at several regional hospi-tals. Study 2 was a multicenter study conducted by the North Central CancerTreatment Group. All 90 patients enrolled in Study 2 received a starting dose of125 mg/m2. Study 3 was a multicenter study that enrolled 166 patients from 30 institutions. The initial dose in Study 3 was 125 mg/m2 but was reduced to100 mg/m2 because the toxicity seen at the 125-mg/m2 dose was perceived to

Camptosar®

irinotecan hydrochloride injectionCamptosar®

irinotecan hydrochloride injection

For Intravenous Use Only

Camptosar®

irinotecan hydrochloride injection

Page 11: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

be greater than that seen in previous studies. All patients in these studies hadmetastatic colorectal cancer, and the majority had disease that recurred or progressed following a 5-FU-based regimen administered for metastatic disease.The results of the individual studies are shown in Table 3.

Table 3. Weekly Dosage Schedule: Study Results

Study

1 2 3

Number of Patients 48 90 64 102

Starting Dose (mg/m2/wk x 4) 125a 125 125 100

Demographics and Treatment AdministrationFemale/Male (%) 46/54 36/64 50/50 51/49

Median Age in years (range) 63 (29-78) 63 (32-81) 61 (42-84) 64 (25-84)

Ethnic Origin (%)White 79 96 81 91African American 12 4 11 5Hispanic 8 0 8 2Oriental/Asian 0 0 0 2

Performance Status (%)0 60 38 59 441 38 48 33 512 2 14 8 5

Primary Tumor (%)Colon 100 71 89 87Rectum 0 29 11 8Unknown 0 0 0 5

Prior 5-FU Therapy (%)For Metastatic Disease 81 66 73 68≤6 months after Adjuvant 15 7 27 28> 6 months after Adjuvant 2 16 0 2Classification Unknown 2 12 0 3

Prior Pelvic/Abdominal Irradiation (%)

Yes 3 29 0 0Other 0 9 2 4None 97 62 98 96

Duration of Treatment with CAMPTOSAR (median, months) 5 4 4 3

Relative Dose Intensityb

(median %) 74 67 73 81

EfficacyConfirmed Objective Response 21 13 14 9Rate (%)c (95% CI) (9.3-32.3) (6.3-20.4) (5.5-22.6) (3.3 -14.3)

Time to Response (median, months) 2.6 1.5 2.8 2.8

Response Duration (median, months) 6.4 5.9 5.6 6.4

Survival (median, months) 10.4 8.1 10.7 9.3

1-Year Survival (%) 46 31 45 43a Nine patients received 150 mg/m2 as a starting dose; two (22.2%) responded to

CAMPTOSAR.b Relative dose intensity for CAMPTOSAR based on planned dose intensity of 100,

83.3, and 66.7 mg/m2/wk corresponding with 150, 125, and 100 mg/m2 startingdoses, respectively.

c Confirmed ≥ 4 to 6 weeks after first evidence of objective response.

In the intent-to-treat analysis of the pooled data across all three studies, 193 of the 304 patients began therapy at the recommended starting dose of 125 mg/m2. Among these 193 patients, 2 complete and 27 partial responses wereobserved, for an overall response rate of 15.0% (95% Confidence Interval [CI],10.0% to 20.1%) at this starting dose. A considerably lower response rate wasseen with a starting dose of 100 mg/m2. The majority of responses wereobserved within the first two cycles of therapy, but responses did occur in latercycles of treatment (one response was observed after the eighth cycle). Themedian response duration for patients beginning therapy at 125 mg/m2 was5.8 months (range, 2.6 to 15.1 months). Of the 304 patients treated in the threestudies, response rates to CAMPTOSAR were similar in males and females andamong patients older and younger than 65 years. Rates were also similar inpatients with cancer of the colon or cancer of the rectum and in patients with single and multiple metastatic sites. The response rate was 18.5% in patients witha performance status of 0 and 8.2% in patients with a performance status of 1 or 2. Patients with a performance status of 3 or 4 have not been studied.Over half of the patients responding to CAMPTOSAR had not responded to prior5-FU. Patients who had received previous irradiation to the pelvis responded toCAMPTOSAR at approximately the same rate as those who had not previouslyreceived irradiation.

Once-Every-3-Week Dosage ScheduleSingle-Arm Studies: Data from an open-label, single-agent, single-arm, multicen-ter, clinical study involving a total of 132 patients support a once-every-3-weekdosage schedule of irinotecan in the treatment of patients with metastatic cancerof the colon or rectum that recurred or progressed following treatment with 5-FU. Patients received a starting dose of 350 mg/m2 given by 30-minute intra-venous infusion once every 3 weeks. Among the 132 previously treated patientsin this trial, the intent-to-treat response rate was 12.1% (95% CI, 7.0% to 18.1%).Randomized Trials: Two multicenter, randomized, clinical studies further supportthe use of irinotecan given by the once-every-3-week dosage schedule in patientswith metastatic colorectal cancer whose disease has recurred or progressed fol-lowing prior 5-FU therapy. In the first study, second-line irinotecan therapy plusbest supportive care was compared with best supportive care alone. In the second study, second-line irinotecan therapy was compared with infusional 5-FU-based therapy. In both studies, irinotecan was administered intravenously at astarting dose of 350 mg/m2 over 90 minutes once every 3 weeks. The startingdose was 300 mg/m2 for patients who were 70 years and older or who had a performance status of 2. The highest total dose permitted was 700 mg. Dose reductions and/or administration delays were permitted in the event ofsevere hematologic and/or nonhematologic toxicities while on treatment. Bestsupportive care was provided to patients in both arms of Study 1 and includedantibiotics, analgesics, corticosteroids, transfusions, psychotherapy, or any othersymptomatic therapy as clinically indicated. In both studies, concomitant med-ications such as antiemetics, atropine, and loperamide were given to patients forprophylaxis and/or management of symptoms from treatment. If late diarrheapersisted for greater than 24 hours despite loperamide, a 7-day course of fluoro-quinolone antibiotic prophylaxis was given. Patients in the control arm of the second study received one of the following 5-FU regimens: (1) LV, 200 mg/m2 IVover 2 hours; followed by 5-FU, 400 mg/m2 IV bolus; followed by 5-FU, 600 mg/m2 continuous IV infusion over 22 hours on days 1 and 2 every 2 weeks;(2) 5-FU, 250 to 300 mg/m2/day protracted continuous IV infusion until toxicity;(3) 5-FU, 2.6 to 3 g/m2 IV over 24 hours every week for 6 weeks with or withoutLV, 20 to 500 mg/m2/day every week IV for 6 weeks with 2-week rest betweencycles. Patients were to be followed every 3 to 6 weeks for 1 year.

A total of 535 patients were randomized in the two studies at 94 centers. Theprimary endpoint in both studies was survival. The studies demonstrated a sig-nificant overall survival advantage for irinotecan compared with best supportivecare (p=0.0001) and infusional 5-FU-based therapy (p=0.035) as shown inFigures 3 and 4. In Study 1, median survival for patients treated with irinotecanwas 9.2 months compared with 6.5 months for patients receiving best support-ive care. In Study 2, median survival for patients treated with irinotecan was 10.8 months compared with 8.5 months for patients receiving infusional 5-FU-based therapy. Multiple regression analyses determined that patients’ base-line characteristics also had a significant effect on survival. When adjusted for

performance status and other baseline prognostic factors, survival amongpatients treated with irinotecan remained significantly longer than in the controlpopulations (p=0.001 for Study 1 and p=0.017 for Study 2). Measurements ofpain, performance status, and weight loss were collected prospectively in the twostudies; however, the plan for the analysis of these data was defined retrospec-tively. When comparing irinotecan with best supportive care in Study 1, thisanalysis showed a statistically significant advantage for irinotecan, with longertime to development of pain (6.9 months versus 2.0 months), time to perform-ance status deterioration (5.7 months versus 3.3 months), and time to > 5%weight loss (6.4 months versus 4.2 months). Additionally, 33.3% (33/99) ofpatients with a baseline performance status of 1 or 2 showed an improvement inperformance status when treated with irinotecan versus 11.3% (7/62) of patientsreceiving best supportive care (p=0.002). Because of the inclusion of patientswith non-measurable disease, intent-to-treat response rates could not beassessed.

In the two randomized studies, the EORTC QLQ-C30 instrument was utilized.At the start of each cycle of therapy, patients completed a questionnaire consist-ing of 30 questions, such as “Did pain interfere with daily activities?” (1 = Not atAll, to 4 = Very Much) and “Do you have any trouble taking a long walk?” (Yesor No). The answers from the 30 questions were converted into 15 subscales,that were scored from 0 to 100, and the global health status subscale that wasderived from two questions about the patient’s sense of general well being in thepast week. In addition to the global health status subscale, there were five func-tional (i.e., cognitive, emotional, social, physical, role) and nine symptom (i.e.,fatigue, appetite loss, pain assessment, insomnia, constipation, dyspnea, nau-sea/vomiting, financial impact, diarrhea) subscales. The results as summarized inTable 5 are based on patients’ worst post-baseline scores. In Study 1, a multivari-ate analysis and univariate analyses of the individual subscales were performedand corrected for multivariate testing. Patients receiving irinotecan reported sig-nificantly better results for the global health status, on two of five functional sub-scales, and on four of nine symptom subscales. As expected, patients receivingirinotecan noted significantly more diarrhea than those receiving best supportivecare. In Study 2, the multivariate analysis on all 15 subscales did not indicate astatistically significant difference between irinotecan and infusional 5-FU.

Table 4. Once-Every-3-Week Dosage Schedule: Study ResultsStudy 1 Study 2

Irinotecan BSCa Irinotecan 5-FU

Number of Patients 189 90 127 129

Demographics and Treatment AdministrationFemale/Male (%) 32/68 42/58 43/57 35/65

Median Age in years (range) 59 (22-75) 62 (34-75) 58 (30-75) 58 (25-75)

Performance Status (%)0 47 31 58 541 39 46 35 432 14 23 8 3

Primary Tumor (%)Colon 55 52 57 62Rectum 45 48 43 38

Prior 5-FU Therapy (%)For Metastatic Disease 70 63 58 68As Adjuvant Treatment 30 37 42 32

Prior Irradiation (%) 26 27 18 20

Duration of Study Treatment(median, months) 4.1 — 4.2 2.8(Log-rank test) (p=0.02)

Relative Dose Intensity(median %)b 94 — 95 81-99

SurvivalSurvival (median, months) 9.2 6.5 10.8 8.5(Log-rank test) (p=0.0001) (p=0.035)a BSC = best supportive careb Relative dose intensity for irinotecan based on planned dose intensity of 116.7

and 100 mg/m2/wk corresponding with 350 and 300 mg/m2 starting doses,respectively.

Camptosar®

irinotecan hydrochloride injectionCamptosar®

irinotecan hydrochloride injectionCamptosar®

irinotecan hydrochloride injection

Table 2. Combination Dosage Schedule: Study Results

Study 1 Study 2Irinotecan +

Bolus 5-FU/LV Bolus 5-FU/LV Irinotecan Irinotecan +weekly x 4 q daily x 5 q weekly x 4 q Infusional Infusional

6 weeks 4 weeks 6 weeks 5-FU/LV 5-FU/LVNumber of Patients 231 226 226 198 187Demographics and Treatment AdministrationFemale/Male (%) 34/65 45/54 35/64 33/67 47/53Median Age in years (range) 62 (25-85) 61 (19-85) 61 (30-87) 62 (27-75) 59 (24-75)Performance Status (%)

0 39 41 46 51 511 46 45 46 42 412 15 13 8 7 8

Primary Tumor (%)Colon 81 85 84 55 65Rectum 17 14 15 45 35

Median Time from Diagnosis to Randomization 1.9 1.7 1.8 4.5 2.7(months, range) (0-161) (0-203) (0.1-185) (0-88) (0-104)Prior Adjuvant 5-FU Therapy (%)

No 89 92 90 74 76Yes 11 8 10 26 24

Median Duration of Study Treatmenta

(months) 5.5 4.1 3.9 5.6 4.5Median Relative Dose Intensity (%)a

Irinotecan 72 — 75 87 —5-FU 71 86 — 86 93

Efficacy ResultsConfirmed Objective Tumor 39 21 18 35 22Response Rateb (%) (p<0.0001)c (p<0.005)c

Median Time to Tumor Progressiond 7.0 4.3 4.2 6.7 4.4(months) (p=0.004)d (p<0.001)d

Median Survival 14.8 12.6 12.0 17.4 14.1(months) (p<0.05)d (p<0.05)d

a Study 1: N=225 (irinotecan/5-FU/LV), N=219 (5-FU/LV), N=223 (irinotecan)Study 2: N=199 (irinotecan/5-FU/LV), N=186 (5-FU/LV)

b Confirmed ≥4 to 6 weeks after first evidence of objective responsec Chi-square test d Log-rank test

Page 12: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Table 5. EORTC QLQ-C30: Mean Worst Post-Baseline Scorea

QLQ-C30 Subscale Study 1 Study 2

Global Health Status 47 37 0.03 53 52 0.9

Functional Scales Cognitive 77 68 0.07 79 83 0.9Emotional 68 64 0.4 64 68 0.9Social 58 47 0.06 65 67 0.9Physical 60 40 0.0003 66 66 0.9Role 53 35 0.02 54 57 0.9Symptom ScalesFatigue 51 63 0.03 47 46 0.9Appetite Loss 37 57 0.0007 35 38 0.9Pain Assessment 41 56 0.009 38 34 0.9Insomnia 39 47 0.3 39 33 0.9Constipation 28 41 0.03 25 19 0.9Dyspnea 31 40 0.2 25 24 0.9Nausea/Vomiting 27 29 0.5 25 16 0.09Financial Impact 22 26 0.5 24 15 0.3Diarrhea 32 19 0.01 32 22 0.2a For the five functional subscales and global health status subscale, higher

scores imply better functioning, whereas, on the nine symptom subscales,higher scores imply more severe symptoms. The subscale scores of eachpatient were collected at each visit until the patient dropped out of the study.

INDICATIONS AND USAGECAMPTOSAR Injection is indicated as a component of first-line therapy

in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. CAMPTOSAR is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred orprogressed following initial fluorouracil-based therapy.CONTRAINDICATIONS

CAMPTOSAR Injection is contraindicated in patients with a known hypersen-sitivity to the drug or its excipients.WARNINGSGeneral

Outside of a well-designed clinical study, CAMPTOSAR Injection should not beused in combination with the “Mayo Clinic” regimen of 5-FU/LV (administrationfor 4-5 consecutive days every 4 weeks) because of reports of increased toxicity,including toxic deaths. CAMPTOSAR should be used as recommended (seeDOSAGE AND ADMINISTRATION, Table 10).

In patients receiving either irinotecan/5-FU/LV or 5-FU/LV in the clinical trials,higher rates of hospitalization, neutropenic fever, thromboembolism, first-cycletreatment discontinuation, and early deaths were observed in patients with abaseline performance status of 2 than in patients with a baseline performancestatus of 0 or 1.Diarrhea

CAMPTOSAR can induce both early and late forms of diarrhea that appear tobe mediated by different mechanisms. Early diarrhea (occurring during or shortlyafter infusion of CAMPTOSAR) is cholinergic in nature. It is usually transient andonly infrequently is severe. It may be accompanied by symptoms of rhinitis,increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinalhyperperistalsis that can cause abdominal cramping. Early diarrhea and othercholinergic symptoms may be prevented or ameliorated by administration ofatropine (see PRECAUTIONS, General, for dosing recommendations foratropine).

Late diarrhea (generally occurring more than 24 hours after administration of CAMPTOSAR) can be life threatening since it may be prolonged and may lead todehydration, electrolyte imbalance, or sepsis. Late diarrhea should be treatedpromptly with loperamide (see PRECAUTIONS, Information for Patients, for dos-ing recommendations for loperamide). Patients with diarrhea should be carefullymonitored, should be given fluid and electrolyte replacement if they becomedehydrated, and should be given antibiotic support if they develop ileus, fever, orsevere neutropenia. After the first treatment, subsequent weekly chemotherapytreatments should be delayed in patients until return of pretreatment bowel func-tion for at least 24 hours without need for antidiarrhea medication. If grade 2, 3,or 4 late diarrhea occurs subsequent doses of CAMPTOSAR should be decreasedwithin the current cycle (see DOSAGE AND ADMINISTRATION).Neutropenia

Deaths due to sepsis following severe neutropenia have been reported in patients treated with CAMPTOSAR. Neutropenic complications should be managed promptly with antibiotic support (see PRECAUTIONS). Therapy withCAMPTOSAR should be temporarily omitted during a cycle of therapy if neutropenic fever occurs or if the absolute neutrophil count drops <1000/mm3.After the patient recovers to an absolute neutrophil count ≥1000/mm3, subse-quent doses of CAMPTOSAR should be reduced depending upon the level of neutropenia observed (see DOSAGE AND ADMINISTRATION).

Routine administration of a colony-stimulating factor (CSF) is not necessary,but physicians may wish to consider CSF use in individual patients experiencingsignificant neutropenia.Patients with Reduced UGT1A1 Activity

Individuals who are homozygous for the UGT1A1*28 allele are at increasedrisk for neutropenia following initiation of CAMPTOSAR treatment. A reduced initial dose should be considered for patients known to be homozygous for theUGT1A1*28 allele (see DOSAGE AND ADMINISTRATION). Heterozygous patients(carriers of one variant allele and one wild-type allele which results in intermedi-ate UGT1A1 activity) may be at increased risk for neutropenia; however, clinicalresults have been variable and such patients have been shown to tolerate normalstarting doses.Hypersensitivity

Hypersensitivity reactions including severe anaphylactic or anaphylactoidreactions have been observed.

Colitis/IleusCases of colitis complicated by ulceration, bleeding, ileus, and infection have

been observed. Patients experiencing ileus should receive prompt antibiotic sup-port (see PRECAUTIONS).Renal Impairment/Renal Failure

Rare cases of renal impairment and acute renal failure have been identified,usually in patients who became volume depleted from severe vomiting and/ordiarrhea.Thromboembolism

Thromboembolic events have been observed in patients receiving irinotecan-containing regimens; the specific cause of these events has not been determined.Pregnancy

CAMPTOSAR may cause fetal harm when administered to a pregnant woman.Radioactivity related to 14C-irinotecan crosses the placenta of rats following intra-venous administration of 10 mg/kg (which in separate studies produced anirinotecan Cmax and AUC about 3 and 0.5 times, respectively, the correspondingvalues in patients administered 125 mg/m2). Administration of 6 mg/kg/day intra-venous irinotecan to rats (which in separate studies produced an irinotecan Cmaxand AUC about 2 and 0.2 times, respectively, the corresponding values in patientsadministered 125 mg/m2) and rabbits (about one-half the recommended humanweekly starting dose on a mg/m2 basis) during the period of organogenesis, isembryotoxic as characterized by increased post-implantation loss and decreasednumbers of live fetuses. Irinotecan was teratogenic in rats at doses greater than1.2 mg/kg/day (which in separate studies produced an irinotecan Cmax and AUCabout 2/3 and 1/40th, respectively, of the corresponding values in patients administered 125 mg/m2) and in rabbits at 6.0 mg/kg/day (about one-half the rec-ommended human weekly starting dose on a mg/m2 basis). Teratogenic effectsincluded a variety of external, visceral, and skeletal abnormalities. Irinotecanadministered to rat dams for the period following organogenesis through wean-ing at doses of 6 mg/kg/day caused decreased learning ability and decreasedfemale body weights in the offspring. There are no adequate and well-controlledstudies of irinotecan in pregnant women. If the drug is used during pregnancy,or if the patient becomes pregnant while receiving this drug, the patient shouldbe apprised of the potential hazard to the fetus. Women of childbearing potentialshould be advised to avoid becoming pregnant while receiving treatment withCAMPTOSAR.PRECAUTIONSGeneralCare of Intravenous Site: CAMPTOSAR Injection is administered by intravenousinfusion. Care should be taken to avoid extravasation, and the infusion site shouldbe monitored for signs of inflammation. Should extravasation occur, flushing thesite with sterile water and applications of ice are recommended.Premedication with Antiemetics: Irinotecan is emetigenic. It is recommended thatpatients receive premedication with antiemetic agents. In clinical studies of theweekly dosage schedule, the majority of patients received 10 mg of dexametha-sone given in conjunction with another type of antiemetic agent, such as a 5-HT3

blocker (e.g., ondansetron or granisetron). Antiemetic agents should be given on the day of treatment, starting at least 30 minutes before administration ofCAMPTOSAR. Physicians should also consider providing patients with anantiemetic regimen (e.g., prochlorperazine) for subsequent use as needed.Treatment of Cholinergic Symptoms: Prophylactic or therapeutic administrationof 0.25 to 1 mg of intravenous or subcutaneous atropine should be considered(unless clinically contraindicated) in patients experiencing rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, abdominal cramping, ordiarrhea (occurring during or shortly after infusion of CAMPTOSAR). Thesesymptoms are expected to occur more frequently with higher irinotecan doses.Patients at Particular Risk: In patients receiving either irinotecan/5-FU/LV or 5-FU/LV in the clinical trials, higher rates of hospitalization, neutropenic fever,thromboembolism, first-cycle treatment discontinuation, and early deaths wereobserved in patients with a baseline performance status of 2 than in patients witha baseline performance status of 0 or 1. Patients who had previously receivedpelvic/abdominal radiation and elderly patients with comorbid conditions shouldbe closely monitored.

The use of CAMPTOSAR in patients with significant hepatic dysfunction hasnot been established. In clinical trials of either dosing schedule, irinotecan wasnot administered to patients with serum bilirubin >2.0 mg/dL, or transaminase>3 times the upper limit of normal if no liver metastasis, or transaminase >5 times the upper limit of normal with liver metastasis. In clinical trials of theweekly dosage schedule, patients with modestly elevated baseline serum totalbilirubin levels (1.0 to 2.0 mg/dL) had a significantly greater likelihood of experi-encing first-cycle grade 3 or 4 neutropenia than those with bilirubin levels thatwere less than 1.0 mg/dL (50.% [19/38] versus 18% [47/226]; p<0.001). (Alsosee CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations:Hepatic Insufficiency). Patients with deficient glucuronidation of bilirubin, such asthose with Gilbert’s syndrome, may be at greater risk of myelosuppression whenreceiving therapy with CAMPTOSAR.

Ketoconazole, enzyme-inducing anticonvulsants and St. John’s Wort areknown to have drug-drug interactions with irinotecan therapy. (See Drug-DrugInteractions sub-section under CLINICAL PHARMACOLOGY)

Irinotecan commonly causes neutropenia, leucopenia, and anemia, any ofwhich may be severe and therefore should not be used in patients with severebone marrow failure.Patients must not be treated with irinotecan until resolution of the bowel obstruc-tion. Patients with hereditary fructose intolerance should not be given CAMPTOSAR, as this product contains sorbitol.Information for Patients

Patients and patients’ caregivers should be informed of the expected toxiceffects of CAMPTOSAR, particularly of its gastrointestinal complications, such asnausea, vomiting, abdominal cramping, diarrhea, and infection. Each patientshould be instructed to have loperamide readily available and to begin treatmentfor late diarrhea (generally occurring more than 24 hours after administration ofCAMPTOSAR) at the first episode of poorly formed or loose stools or the earli-est onset of bowel movements more frequent than normally expected for thepatient. One dosage regimen for loperamide used in clinical trials consisted of thefollowing (Note: This dosage regimen exceeds the usual dosage recommendations for loperamide.): 4 mg at the first onset of late diarrhea andthen 2 mg every 2 hours until the patient is diarrhea-free for at least 12 hours.Loperamide is not recommended to be used for more than 48 consecutive hoursat these doses, because of the risk of paralytic ileus. During the night, the patientmay take 4 mg of loperamide every 4 hours. Premedication with loperamide isnot recommended. The use of drugs with laxative properties should be avoidedbecause of the potential for exacerbation of diarrhea. Patients should be advisedto contact their physician to discuss any laxative use.

Patients should be instructed to contact their physician or nurse if any of thefollowing occur: diarrhea for the first time during treatment; black or bloody

stools; symptoms of dehydration such as lightheadedness, dizziness, or faint-ness; inability to take fluids by mouth due to nausea or vomiting; inability to getdiarrhea under control within 24 hours; or fever or evidence of infection.

Patients should be warned about the potential for dizziness or visual disturbances which may occur within 24 hours following the administration ofCAMPTOSAR, and advised not to drive or operate machinery if these symptomsoccur.

Patients should be alerted to the possibility of alopecia.Laboratory Tests

Careful monitoring of the white blood cell count with differential, hemoglobin,and platelet count is recommended before each dose of CAMPTOSAR.Drug Interactions

The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea,would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.

Patients who have previously received pelvic/abdominal irradiation are at increased risk of severe myelosuppression following the administration ofCAMPTOSAR. The concurrent administration of CAMPTOSAR with irradiationhas not been adequately studied and is not recommended.

Lymphocytopenia has been reported in patients receiving CAMPTOSAR, andit is possible that the administration of dexamethasone as antiemetic prophylaxismay have enhanced the likelihood of this effect. However, serious opportunisticinfections have not been observed, and no complications have specifically beenattributed to lymphocytopenia.

Hyperglycemia has also been reported in patients receiving CAMPTOSAR.Usually, this has been observed in patients with a history of diabetes mellitus orevidence of glucose intolerance prior to administration of CAMPTOSAR. It isprobable that dexamethasone, given as antiemetic prophylaxis, contributed tohyperglycemia in some patients.

The incidence of akathisia in clinical trials of the weekly dosage schedule wasgreater (8.5%, 4/47 patients) when prochlorperazine was administered on thesame day as CAMPTOSAR than when these drugs were given on separate days(1.3%, 1/80 patients). The 8.5% incidence of akathisia, however, is within therange reported for use of prochlorperazine when given as a premedication forother chemotherapies.

It would be expected that laxative use during therapy with CAMPTOSAR wouldworsen the incidence or severity of diarrhea, but this has not been studied.

In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diureticsduring dosing with CAMPTOSAR and, certainly, during periods of active vomit-ing or diarrhea.Drug-Laboratory Test Interactions

There are no known interactions between CAMPTOSAR and laboratory tests.Carcinogenesis, Mutagenesis & Impairment of Fertility

Long-term carcinogenicity studies with irinotecan were not conducted. Ratswere, however, administered intravenous doses of 2 mg/kg or 25 mg/kg irinote-can once per week for 13 weeks (in separate studies, the 25 mg/kg dose pro-duced an irinotecan Cmax and AUC that were about 7.0 times and 1.3 times therespective values in patients administered 125 mg/m2 weekly) and were thenallowed to recover for 91 weeks. Under these conditions, there was a significantlinear trend with dose for the incidence of combined uterine horn endometrialstromal polyps and endometrial stromal sarcomas. Neither irinotecan nor SN-38was mutagenic in the in vitro Ames assay. Irinotecan was clastogenic both in vitro(chromosome aberrations in Chinese hamster ovary cells) and in vivo (micronu-cleus test in mice). No significant adverse effects on fertility and general repro-ductive performance were observed after intravenous administration of irinote-can in doses of up to 6 mg/kg/day to rats and rabbits. However, atrophy of malereproductive organs was observed after multiple daily irinotecan doses both inrodents at 20 mg/kg (which in separate studies produced an irinotecan Cmax andAUC about 5 and 1 times, respectively, the corresponding values in patientsadministered 125 mg/m2 weekly) and dogs at 0.4 mg/kg (which in separate stud-ies produced an irinotecan Cmax and AUC about one-half and 1/15th, respectively,the corresponding values in patients administered 125 mg/m2 weekly).Pregnancy

Pregnancy Category D—see WARNINGS.Nursing Mothers

Radioactivity appeared in rat milk within 5 minutes of intravenous administra-tion of radiolabeled irinotecan and was concentrated up to 65-fold at 4 hours afteradministration relative to plasma concentrations. Because many drugs areexcreted in human milk and because of the potential for serious adverse reac-tions in nursing infants, it is recommended that nursing be discontinued whenreceiving therapy with CAMPTOSAR.Pediatric Use

The effectiveness of irinotecan in pediatric patients has not been established.Results from two open-label, single arm studies were evaluated. One hundred andseventy children with refractory solid tumors were enrolled in one phase 2 trial inwhich 50 mg/m2 of irinotecan was infused for 5 consecutive days every 3 weeks.Grade 3-4 neutropenia was experienced by 54 (31.8%) patients. Neutropenia wascomplicated by fever in 15 (8.8%) patients. Grade 3-4 diarrhea was observed in 35(20.6%) patients. This adverse event profile was comparable to that observed inadults. In the second phase 2 trial of 21 children with previously untreated rhab-domyosarcoma, 20 mg/m2 of irinotecan was infused for 5 consecutive days onweeks 0, 1, 3 and 4. This single agent therapy was followed by multimodal ther-apy. Accrual to the single agent irinotecan phase was halted due to the high rate(28.6%) of progressive disease and the early deaths (14%). The adverse event pro-file was different in this study from that observed in adults; the most significantgrade 3 or 4 adverse events were dehydration experienced by 6 patients (28.6%)associated with severe hypokalemia in 5 patients (23.8%) and hyponatremia in 3patients (14.3%); in addition Grade 3-4 infection was reported in 5 patients (23.8%)(across all courses of therapy and irrespective of causal relationship).

Pharmacokinetic parameters for irinotecan and SN-38 were determined in 2pediatric solid-tumor trials at dose levels of 50 mg/m2 (60-min infusion, n=48)and 125 mg/m2 (90-min infusion, n=6). Irinotecan clearance (mean ± S.D.) was17.3 ± 6.7 L/h/m2 for the 50 mg/m2 dose and 16.2 ± 4.6 L/h/m2 for the 125mg/m2 dose, which is comparable to that in adults. Dose-normalized SN-38 AUCvalues were comparable between adults and children. Minimal accumulation ofirinotecan and SN-38 was observed in children on daily dosing regimens [daily x5 every 3 weeks or (daily x 5) x 2 weeks every 3 weeks].Geriatric Use

Patients greater than 65 years of age should be closely monitored because ofa greater risk of late diarrhea in this population (see CLINICAL PHARMACOLOGY,Pharmacokinetics in Special Populations and ADVERSE REACTIONS, Overviewof Adverse Events). The starting dose of CAMPTOSAR in patients 70 years andolder for the once-every-3-week dosage schedule should be 300 mg/m2 (seeDOSAGE AND ADMINISTRATION).

Camptosar®

irinotecan hydrochloride injectionCamptosar®

irinotecan hydrochloride injectionCamptosar®

irinotecan hydrochloride injection

Irin

otec

an

BSC

p-va

lue

Irin

otec

an

5-FU

p-va

lue

10

Page 13: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

ADVERSE REACTIONSFirst-Line Combination Therapy

A total of 955 patients with metastatic colorectal cancer received the recom-mended regimens of irinotecan in combination with 5-FU/LV, 5-FU/LV alone, oririnotecan alone. In the two phase 3 studies, 370 patients received irinotecan incombination with 5-FU/LV, 362 patients received 5-FU/LV alone, and 223 patientsreceived irinotecan alone. (See Table 10 in DOSAGE AND ADMINISTRATION forrecommended combination-agent regimens.)

In Study 1, 49 (7.3%) patients died within 30 days of last study treatment: 21 (9.3%) received irinotecan in combination with 5-FU/LV, 15 (6.8%) received5-FU/LV alone, and 13 (5.8%) received irinotecan alone. Deaths potentially relatedto treatment occurred in 2 (0.9%) patients who received irinotecan in combina-tion with 5-FU/LV (2 neutropenic fever/sepsis), 3 (1.4%) patients who received5-FU/LV alone (1 neutropenic fever/sepsis, 1 CNS bleeding during thrombocy-topenia, 1 unknown) and 2 (0.9%) patients who received irinotecan alone (2 neu-tropenic fever). Deaths from any cause within 60 days of first study treatmentwere reported for 15 (6.7%) patients who received irinotecan in combination with5-FU/LV, 16 (7.3%) patients who received 5-FU/LV alone, and 15 (6.7%) patientswho received irinotecan alone. Discontinuations due to adverse events werereported for 17 (7.6%) patients who received irinotecan in combination with 5-FU/LV, 14 (6.4%) patients who received 5-FU/LV alone, and 26 (11.7%) patientswho received irinotecan alone.

In Study 2, 10 (3.5%) patients died within 30 days of last study treatment: 6 (4.1%) received irinotecan in combination with 5-FU/LV and 4 (2.8%) received5-FU/LV alone. There was one potentially treatment-related death, which occurredin a patient who received irinotecan in combination with 5-FU/LV (0.7%, neu-tropenic sepsis). Deaths from any cause within 60 days of first study treatmentwere reported for 3 (2.1%) patients who received irinotecan in combination with5-FU/LV and 2 (1.4%) patients who received 5-FU/LV alone. Discontinuations dueto adverse events were reported for 9 (6.2%) patients who received irinotecan incombination with 5-FU/LV and 1 (0.7%) patient who received 5-FU/LV alone.

The most clinically significant adverse events for patients receiving irinotecan-based therapy were diarrhea, nausea, vomiting, neutropenia, and alopecia. Themost clinically significant adverse events for patients receiving 5-FU/LV therapywere diarrhea, neutropenia, neutropenic fever, and mucositis. In Study 1, grade4 neutropenia, neutropenic fever (defined as grade 2 fever and grade 4 neutrope-nia), and mucositis were observed less often with weekly irinotecan/5-FU/LV thanwith monthly administration of 5-FU/LV.

Tables 6 and 7 list the clinically relevant adverse events reported in Studies 1and 2, respectively.Second-Line Single-Agent TherapyWeekly Dosage Schedule

In three clinical studies evaluating the weekly dosage schedule, 304 patientswith metastatic carcinoma of the colon or rectum that had recurred or progressedfollowing 5-FU-based therapy were treated with CAMPTOSAR. Seventeen of thepatients died within 30 days of the administration of CAMPTOSAR; in five cases(1.6%, 5/304), the deaths were potentially drug-related. These five patients experienced a constellation of medical events that included known effects ofCAMPTOSAR. One of these patients died of neutropenic sepsis without fever.Neutropenic fever occurred in nine (3.0%) other patients; these patients recov-ered with supportive care.

One hundred nineteen (39.1%) of the 304 patients were hospitalized a total of156 times because of adverse events; 81 (26.6%) patients were hospitalized forevents judged to be related to administration of CAMPTOSAR. The primary rea-sons for drug-related hospitalization were diarrhea, with or without nausea and/orvomiting (18.4%); neutropenia/leukopenia, with or without diarrhea and/or fever(8.2%); and nausea and/or vomiting (4.9%).

Table 7. Study 2: Percent (%) of Patients Experiencing ClinicallyRelevant Adverse Events in Combination Therapiesa

Study 2

Irinotecan +5-FU/LV 5-FU/LV

Infusional d 1&2 Infusional d 1&2q 2 weeks q 2 weeks

Adverse Event N=145 N=143

Grade 1-4 Grade 3&4 Grade 1-4 Grade 3&4

TOTAL Adverse Events 100 72.4 100 39.2

GASTROINTESTINALDiarrhealate 72.4 14.4 44.8 6.3grade 3 — 10.3 — 4.2grade 4 — 4.1 — 2.1

Cholinergic syndromeb 28.3 1.4 0.7 0Nausea 66.9 2.1 55.2 3.5Abdominal pain 17.2 2.1 16.8 0.7Vomiting 44.8 3.5 32.2 2.8Anorexia 35.2 2.1 18.9 0.7Constipation 30.3 0.7 25.2 1.4Mucositis 40.0 4.1 28.7 2.8

HEMATOLOGICNeutropenia 82.5 46.2 47.9 13.4

grade 3 — 36.4 — 12.7grade 4 — 9.8 — 0.7

Leukopenia 81.3 17.4 42.0 3.5Anemia 97.2 2.1 90.9 2.1Neutropenic fever — 3.4 — 0.7Thrombocytopenia 32.6 0 32.2 0Neutropenic infection — 2.1 — 0

BODY AS A WHOLEAsthenia 57.9 9.0 48.3 4.2Pain 64.1 9.7 61.5 8.4Fever 22.1 0.7 25.9 0.7Infection 35.9 7.6 33.6 3.5

METABOLIC & NUTRITIONAL↑ Bilirubin 19.1 3.5 35.9 10.6

Table 7. Study 2: Percent (%) of Patients Experiencing ClinicallyRelevant Adverse Events in Combination Therapiesa (continued)

Study 2

Irinotecan +5-FU/LV 5-FU/LV

Infusional d 1&2 Infusional d 1&2q 2 weeks q 2 weeks

Adverse Event N=145 N=143

Grade 1-4 Grade 3&4 Grade 1-4 Grade 3&4

DERMATOLOGIC

Hand & foot syndrome 10.3 0.7 12.6 0.7Cutaneous signs 17.2 0.7 20.3 0Alopeciac 56.6 — 16.8 —

RESPIRATORYDyspnea 9.7 1.4 4.9 0

CARDIOVASCULARHypotension 3.4 1.4 0.7 0Thromboembolic events d 11.7 — 5.6 —

a Severity of adverse events based on NCI CTC (version 1.0)b Includes rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flush-

ing, abdominal cramping or diarrhea (occurring during or shortly after infu-sion of irinotecan)

c Complete hair loss = Grade 2d Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular

accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myo-cardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonaryembolus, sudden death, thrombophlebitis, thrombosis, vascular disorder.

Adjustments in the dose of CAMPTOSAR were made during the cycle of treat-ment and for subsequent cycles based on individual patient tolerance. The firstdose of at least one cycle of CAMPTOSAR was reduced for 67% of patients whobegan the studies at the 125-mg/m2 starting dose. Within-cycle dose reductionswere required for 32% of the cycles initiated at the 125-mg/m2 dose level. Themost common reasons for dose reduction were late diarrhea, neutropenia, andleukopenia. Thirteen (4.3%) patients discontinued treatment with CAMPTOSARbecause of adverse events. The adverse events in Table 8 are based on the expe-rience of the 304 patients enrolled in the three studies described in the CLINICALSTUDIES, Studies Evaluating the Weekly Dosage Schedule, section.

Table 8. Adverse Events Occurring in >10% of 304 PreviouslyTreated Patients with Metastatic Carcinoma

of the Colon or Rectuma

% of Patients ReportingBody System & Event

NCI Grades 1-4 NCI Grades 3 & 4

GASTROINTESTINALDiarrhea (late)b 88 317-9 stools/day (grade 3) — (16)≥10 stools/day (grade 4) — (14)

Nausea 86 17Vomiting 67 12Anorexia 55 6Diarrhea (early)c 51 8Constipation 30 2Flatulence 12 0Stomatitis 12 1Dyspepsia 10 0

HEMATOLOGICLeukopenia 63 28Anemia 60 7Neutropenia 54 26500 to <1000/mm3 (grade 3) — (15)<500/mm3 (grade 4) — (12)

BODY AS A WHOLEAsthenia 76 12Abdominal cramping/pain 57 16Fever 45 1Pain 24 2Headache 17 1Back pain 14 2Chills 14 0Minor infection d 14 0Edema 10 1Abdominal enlargement 10 0

METABOLIC & NUTRITIONAL↓ Body weight 30 1Dehydration 15 4↑ Alkaline phosphatase 13 4↑ SGOT 10 1

DERMATOLOGICAlopecia 60 NAe

Sweating 16 0Rash 13 1

RESPIRATORYDyspnea 22 4↑ Coughing 17 0Rhinitis 16 0

NEUROLOGICInsomnia 19 0Dizziness 15 0

CARDIOVASCULARVasodilation (flushing) 11 0

a Severity of adverse events based on NCI CTC (version 1.0)b Occurring >24 hours after administration of CAMPTOSARc Occurring ≤24 hours after administration of CAMPTOSARd Primarily upper respiratory infectionse Not applicable; complete hair loss = NCI grade 2

Camptosar®

irinotecan hydrochloride injectionCamptosar®

irinotecan hydrochloride injectionCamptosar®

irinotecan hydrochloride injection

Table 6. Study 1: Percent (%) of Patients Experiencing Clinically Relevant Adverse Events in Combination Therapiesa

Study 1

Irinotecan + Bolus 5-FU/LV Bolus 5-FU/LV Irinotecanweekly x 4 daily x 5 weekly x 4q 6 weeks q 4 weeks q 6 weeks

Adverse Event N=225 N=219 N=223

Grade 1-4 Grade 3&4 Grade 1-4 Grade 3&4 Grade 1-4 Grade 3&4

TOTAL Adverse Events 100 53.3 100 45.7 99.6 45.7

GASTROINTESTINALDiarrhea

late 84.9 22.7 69.4 13.2 83.0 31.0grade 3 — 15.1 — 5.9 — 18.4grade 4 — 7.6 — 7.3 — 12.6

early 45.8 4.9 31.5 1.4 43.0 6.7Nausea 79.1 15.6 67.6 8.2 81.6 16.1Abdominal pain 63.1 14.6 50.2 11.5 67.7 13.0Vomiting 60.4 9.7 46.1 4.1 62.8 12.1Anorexia 34.2 5.8 42.0 3.7 43.9 7.2Constipation 41.3 3.1 31.5 1.8 32.3 0.4Mucositis 32.4 2.2 76.3 16.9 29.6 2.2

HEMATOLOGICNeutropenia 96.9 53.8 98.6 66.7 96.4 31.4

grade 3 — 29.8 — 23.7 — 19.3grade 4 — 24.0 — 42.5 — 12.1

Leukopenia 96.9 37.8 98.6 23.3 96.4 21.5Anemia 96.9 8.4 98.6 5.5 96.9 4.5Neutropenic fever — 7.1 — 14.6 — 5.8Thrombocytopenia 96.0 2.6 98.6 2.7 96.0 1.7Neutropenic infection — 1.8 — 0 — 2.2

BODY AS A WHOLEAsthenia 70.2 19.5 64.4 11.9 69.1 13.9Pain 30.7 3.1 26.9 3.6 22.9 2.2Fever 42.2 1.7 32.4 3.6 43.5 0.4Infection 22.2 0 16.0 1.4 13.9 0.4

METABOLIC & NUTRITIONAL↑ Bilirubin 87.6 7.1 92.2 8.2 83.9 7.2

DERMATOLOGICExfoliative dermatitis 0.9 0 3.2 0.5 0 0Rash 19.1 0 26.5 0.9 14.3 0.4Alopecia b 43.1 — 26.5 — 46.1 —

RESPIRATORYDyspnea 27.6 6.3 16.0 0.5 22.0 2.2Cough 26.7 1.3 18.3 0 20.2 0.4Pneumonia 6.2 2.7 1.4 1.0 3.6 1.3

NEUROLOGICDizziness 23.1 1.3 16.4 0 21.1 1.8Somnolence 12.4 1.8 4.6 1.8 9.4 1.3Confusion 7.1 1.8 4.1 0 2.7 0

CARDIOVASCULARVasodilation 9.3 0.9 5.0 0 9.0 0Hypotension 5.8 1.3 2.3 0.5 5.8 1.7Thromboembolic eventsc 9.3 — 11.4 — 5.4 —

a Severity of adverse events based on NCI CTC (version 1.0)b Complete hair loss = Grade 2c Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest,

myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder.

11

Page 14: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Once-Every-3-Week Dosage ScheduleA total of 535 patients with metastatic colorectal cancer whose disease had

recurred or progressed following prior 5-FU therapy participated in the two phase3 studies: 316 received irinotecan, 129 received 5-FU, and 90 received best sup-portive care. Eleven (3.5%) patients treated with irinotecan died within 30 daysof treatment. In three cases (1%, 3/316), the deaths were potentially related toirinotecan treatment and were attributed to neutropenic infection, grade 4 diar-rhea, and asthenia, respectively. One (0.8%, 1/129) patient treated with 5-FU diedwithin 30 days of treatment; this death was attributed to grade 4 diarrhea.

Hospitalizations due to serious adverse events (whether or not related to studytreatment) occurred at least once in 60% (188/316) of patients who receivedirinotecan, 63% (57/90) who received best supportive care, and 39% (50/129)who received 5-FU-based therapy. Eight percent of patients treated with irinote-can and 7% treated with 5-FU-based therapy discontinued treatment due toadverse events.

Of the 316 patients treated with irinotecan, the most clinically significantadverse events (all grades, 1-4) were diarrhea (84%), alopecia (72%), nausea(70%), vomiting (62%), cholinergic symptoms (47%), and neutropenia (30%).Table 9 lists the grade 3 and 4 adverse events reported in the patients enrolled toall treatment arms of the two studies described in the CLINICAL STUDIES,Studies Evaluating the Once-Every-3-Week Dosage Schedule, section.

Table 9. Percent Of Patients Experiencing Grade 3 & 4 Adverse Events InComparative Studies Of Once-Every-3-Week Irinotecan Therapya

Study 1 Study 2Irinotecan BSCb Irinotecan 5-FU

Adverse Event N=189 N=90 N=127 N=129

TOTAL Grade 3/4 Adverse Events 79 67 69 54

GASTROINTESTINALDiarrhea 22 6 22 11Vomiting 14 8 14 5Nausea 14 3 11 4Abdominal pain 14 16 9 8Constipation 10 8 8 6Anorexia 5 7 6 4Mucositis 2 1 2 5

HEMATOLOGICLeukopenia/Neutropenia 22 0 14 2Anemia 7 6 6 3Hemorrhage 5 3 1 3Thrombocytopenia 1 0 4 2

Infectionwithout grade 3/4 neutropenia 8 3 1 4with grade 3/4 neutropenia 1 0 2 0

Feverwithout grade 3/4 neutropenia 2 1 2 0with grade 3/4 neutropenia 2 0 4 2

BODY AS A WHOLEPain 19 22 17 13Asthenia 15 19 13 12

METABOLIC & NUTRITIONALHepaticc 9 7 9 6

DERMATOLOGICHand & foot syndrome 0 0 0 5Cutaneous signsd 2 0 1 3

RESPIRATORYe 10 8 5 7

NEUROLOGIC f 12 13 9 4

CARDIOVASCULARg 9 3 4 2

OTHERh 32 28 12 14a Severity of adverse events based on NCI CTC (version 1.0)b BSC = best supportive carec Hepatic includes events such as ascites and jaundiced Cutaneous signs include events such as rashe Respiratory includes events such as dyspnea and coughf Neurologic includes events such as somnolenceg Cardiovascular includes events such as dysrhythmias, ischemia, and

mechanical cardiac dysfunctionh Other includes events such as accidental injury, hepatomegaly, syncope,

vertigo, and weight loss

Overview of Adverse EventsGastrointestinal: Nausea, vomiting, and diarrhea are common adverse events fol-lowing treatment with CAMPTOSAR and can be severe. When observed, nauseaand vomiting usually occur during or shortly after infusion of CAMPTOSAR. Inthe clinical studies testing the every 3-week-dosage schedule, the median time to the onset of late diarrhea was 5 days after irinotecan infusion. In the clinicalstudies evaluating the weekly dosage schedule, the median time to onset of latediarrhea was 11 days following administration of CAMPTOSAR. For patientsstarting treatment at the 125-mg/m2 weekly dose, the median duration of anygrade of late diarrhea was 3 days. Among those patients treated at the 125-mg/m2

weekly dose who experienced grade 3 or 4 late diarrhea, the median duration ofthe entire episode of diarrhea was 7 days. The frequency of grade 3 or 4 late diar-rhea was somewhat greater in patients starting treatment at 125 mg/m2 than inpatients given a 100-mg/m2 weekly starting dose (34% [65/193] versus 23%[24/102]; p=0.08). The frequency of grade 3 and 4 late diarrhea by age was sig-nificantly greater in patients ≥65 years than in patients <65 years (40% [53/133]versus 23% [40/171]; p=0.002). In one study of the weekly dosage treatment,the frequency of grade 3 and 4 late diarrhea was significantly greater in male thanin female patients (43% [25/58] versus 16% [5/32]; p=0.01), but there were nogender differences in the frequency of grade 3 and 4 late diarrhea in the other twostudies of the weekly dosage treatment schedule. Colonic ulceration, sometimeswith gastrointestinal bleeding, has been observed in association with administra-tion of CAMPTOSAR.Hematology: CAMPTOSAR commonly causes neutropenia, leukopenia (includinglymphocytopenia), and anemia. Serious thrombocytopenia is uncommon. Whenevaluated in the trials of weekly administration, the frequency of grade 3 and 4neutropenia was significantly higher in patients who received previouspelvic/abdominal irradiation than in those who had not received such irradiation(48% [13/27] versus 24% [67/277]; p=0.04). In these same studies, patientswith baseline serum total bilirubin levels of 1.0 mg/dL or more also had a signif-

icantly greater likelihood of experiencing first-cycle grade 3 or 4 neutropenia thanthose with bilirubin levels that were less than 1.0 mg/dL (50% [19/38] versus18% [47/266]; p<0.001). There were no significant differences in the frequencyof grade 3 and 4 neutropenia by age or gender. In the clinical studies evaluatingthe weekly dosage schedule, neutropenic fever (concurrent NCI grade 4 neu-tropenia and fever of grade 2 or greater) occurred in 3% of the patients; 6% of patients received G-CSF for the treatment of neutropenia. NCI grade 3 or 4 anemia was noted in 7% of the patients receiving weekly treatment; blood trans-fusions were given to 10% of the patients in these trials. Body as a Whole: Asthenia, fever, and abdominal pain are generally the mostcommon events of this type.Cholinergic Symptoms: Patients may have cholinergic symptoms of rhinitis,increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinalhyperperistalsis that can cause abdominal cramping and early diarrhea. If thesesymptoms occur, they manifest during or shortly after drug infusion. They arethought to be related to the anticholinesterase activity of the irinotecan parentcompound and are expected to occur more frequently with higher irinotecandoses.Hepatic: In the clinical studies evaluating the weekly dosage schedule, NCI grade3 or 4 liver enzyme abnormalities were observed in fewer than 10% of patients.These events typically occur in patients with known hepatic metastases.Dermatologic: Alopecia has been reported during treatment with CAMPTOSAR.Rashes have also been reported but did not result in discontinuation of treatment.Respiratory: Severe pulmonary events are infrequent. In the clinical studies eval-uating the weekly dosage schedule, NCI grade 3 or 4 dyspnea was reported in4% of patients. Over half the patients with dyspnea had lung metastases; theextent to which malignant pulmonary involvement or other preexisting lung dis-ease may have contributed to dyspnea in these patients is unknown.

Interstitial pulmonary disease presenting as pulmonary infiltrates is uncom-mon during irinotecan therapy. Interstitial pulmonary disease can be fatal. Riskfactors possibly associated with the development of interstitial pulmonary dis-ease include pre-existing lung disease, use of pneumotoxic drugs, radiation ther-apy, and colony stimulating factors. Patients with risk factors should be closelymonitored for respiratory symptoms before and during irinotecan therapy.Neurologic: Insomnia and dizziness can occur, but are not usually considered tobe directly related to the administration of CAMPTOSAR. Dizziness may some-times represent symptomatic evidence of orthostatic hypotension in patients withdehydration.Cardiovascular: Vasodilation (flushing) may occur during administration ofCAMPTOSAR. Bradycardia may also occur, but has not required intervention.These effects have been attributed to the cholinergic syndrome sometimesobserved during or shortly after infusion of CAMPTOSAR. Thromboembolicevents have been observed in patients receiving CAMPTOSAR; the specific causeof these events has not been determined.Other Non-U.S. Clinical Trials

Irinotecan has been studied in over 1100 patients in Japan. Patients in thesestudies had a variety of tumor types, including cancer of the colon or rectum, andwere treated with several different doses and schedules. In general, the types oftoxicities observed were similar to those seen in U.S. trials with CAMPTOSAR.There is some information from Japanese trials that patients with considerableascites or pleural effusions were at increased risk for neutropenia or diarrhea. Apotentially life-threatening pulmonary syndrome, consisting of dyspnea, fever,and a reticulonodular pattern on chest x-ray, was observed in a small percentageof patients in early Japanese studies. The contribution of irinotecan to these pre-liminary events was difficult to assess because these patients also had lungtumors and some had preexisting nonmalignant pulmonary disease. As a resultof these observations, however, clinical studies in the United States have enrolledfew patients with compromised pulmonary function, significant ascites, or pleu-ral effusions.Post-Marketing Experience

The following events have been identified during postmarketing use of CAMPTOSAR in clinical practice. Infrequent cases of ulcerative and ischemic coli-tis have been observed. This can be complicated by ulceration, bleeding, ileus,obstruction, and infection, including typhlitis. Patients experiencing ileus shouldreceive prompt antibiotic support (see PRECAUTIONS). Rare cases of intestinalperforation have been reported. Rare cases of symptomatic pancreatitis orasymptomatic elevated pancreatic enzymes have been observed.

Hypersensitivity reactions including severe anaphylactic or anaphylactoidreactions have also been observed (see WARNINGS).

Rare cases of hyponatremia mostly related with diarrhea and vomiting havebeen reported. Transient and mild to moderate increases in serum levels oftransaminases (i.e., AST and ALT) in the absence of progressive liver metastasis;transient increase of amylase and occasionally transient increase of lipase havebeen very rarely reported.

Infrequent cases of renal insufficiency including acute renal failure, hypoten-sion or circulatory failure have been observed in patients who experiencedepisodes of dehydration associated with diarrhea and/or vomiting, or sepsis (seeWARNINGS).

Early effects such as muscular contraction or cramps and paresthesia havebeen reported.

OVERDOSAGEIn U.S. phase 1 trials, single doses of up to 345 mg/m2 of irinotecan were

administered to patients with various cancers. Single doses of up to 750 mg/m2

of irinotecan have been given in non-U.S. trials. The adverse events in thesepatients were similar to those reported with the recommended dosage and regi-men. There have been reports of overdosage at doses up to approximately twicethe recommended therapeutic dose, which may be fatal. The most significantadverse reactions reported were severe neutropenia and severe diarrhea. Thereis no known antidote for overdosage of CAMPTOSAR. Maximum supportive careshould be instituted to prevent dehydration due to diarrhea and to treat any infec-tious complications.

DOSAGE AND ADMINISTRATIONDosage in Patients with Reduced UGT1A1 ActivityWhen administered in combination with other agents, or as a single-agent, areduction in the starting dose by at least one level of CAMPTOSAR should be con-sidered for patients known to be homozygous for the UGT1A1*28 allele (seeCLINICAL PHARMACOLOGY and WARNINGS). However, the precise dose reduc-tion in this patient population is not known and subsequent dose modificationsshould be considered based on individual patient tolerance to treatment (seeTables 10-13).Combination-Agent DosageDosage RegimensCAMPTOSAR Injection in Combination with 5-Fluorouracil (5-FU) andLeucovorin (LV)

CAMPTOSAR should be administered as an intravenous infusion over 90 min-utes (see Preparation of Infusion Solution). For all regimens, the dose of LVshould be administered immediately after CAMPTOSAR, with the administrationof 5-FU to occur immediately after receipt of LV. CAMPTOSAR should be used asrecommended; the currently recommended regimens are shown in Table 10.

Dosing for patients with bilirubin >2 mg/dL cannot be recommended becausethere is insufficient information to recommend a dose in these patients. It is rec-ommended that patients receive premedication with antiemetic agents.Prophylactic or therapeutic administration of atropine should be considered inpatients experiencing cholinergic symptoms. See PRECAUTIONS, General.Dose Modifications

Patients should be carefully monitored for toxicity and assessed prior to eachtreatment. Doses of CAMPTOSAR and 5-FU should be modified as necessary toaccommodate individual patient tolerance to treatment. Based on therecommended dose-levels described in Table 10, Combination-Agent DosageRegimens & Dose Modifications, subsequent doses should be adjusted as sug-gested in Table 11, Recommended Dose Modifications for CombinationSchedules. All dose modifications should be based on the worst preceding toxicity. After the first treatment, patients with active diarrhea shouldreturn to pre-treatment bowel function without requiring anti-diarrhea medica-tions for at least 24 hours before the next chemotherapy administration.

A new cycle of therapy should not begin until the toxicity has recovered to NCIgrade 1 or less. Treatment may be delayed 1 to 2 weeks to allow for recoveryfrom treatment-related toxicity. If the patient has not recovered, considerationshould be given to discontinuing therapy. Provided intolerable toxicity does notdevelop, treatment with additional cycles of CAMPTOSAR/5-FU/LV may be con-tinued indefinitely as long as patients continue to experience clinical benefit.Single-Agent Dosage SchedulesDosage Regimens

CAMPTOSAR should be administered as an intravenous infusion over 90 min-utes for both the weekly and once-every-3-week dosage schedules (seePreparation of Infusion Solution). Single-agent dosage regimens are shown inTable 12.

A reduction in the starting dose by one dose level of CAMPTOSAR may beconsidered for patients with any of the following conditions: age ≥65 years, priorpelvic/abdominal radiotherapy, performance status of 2, or increased bilirubinlevels. Dosing for patients with bilirubin >2 mg/dL cannot be recommendedbecause there is insufficient information to recommend a dose in these patients.

It is recommended that patients receive premedication with antiemetic agents.Prophylactic or therapeutic administration of atropine should be considered inpatients experiencing cholinergic symptoms. See PRECAUTIONS, General.Dose Modifications

Patients should be carefully monitored for toxicity and doses of CAMPTOSARshould be modified as necessary to accommodate individual patient tolerance totreatment. Based on recommended dose-levels described in Table 12, Single-Agent Regimens of CAMPTOSAR and Dose Modifications, subsequent dosesshould be adjusted as suggested in Table 13, Recommended Dose Modificationsfor Single-Agent Schedules. All dose modifications should be based on the worstpreceding toxicity.

A new cycle of therapy should not begin until the toxicity has recovered to NCIgrade 1 or less. Treatment may be delayed 1 to 2 weeks to allow for recovery fromtreatment-related toxicity. If the patient has not recovered, consideration shouldbe given to discontinuing this combination therapy. Provided intolerable toxicitydoes not develop, treatment with additional cycles of CAMPTOSAR may be con-tinued indefinitely as long as patients continue to experience clinical benefit.

Camptosar®

irinotecan hydrochloride injectionCamptosar®

irinotecan hydrochloride injectionCamptosar®

irinotecan hydrochloride injection

Table 10. Combination-Agent Dosage Regimens & Dose Modificationsa

Regimen 1 CAMPTOSAR 125 mg/m2 IV over 90 min, d 1,8,15,226-wk cycle with LV 20 mg/m2 IV bolus, d 1,8,15,22 bolus 5-FU/LV 5-FU 500 mg/m2 IV bolus, d 1,8,15,22(next cycle Starting Dose & Modified Dose Levels (mg/m2)begins on

Starting Dose Dose Level -1 Dose Level -2day 43)

CAMPTOSAR 125 100 75LV 20 20 205-FU 500 400 300

Regimen 2 CAMPTOSAR 180 mg/m2 IV over 90 min, d 1,15,29 6-wk cycle LV 200 mg/m2 IV over 2 h, d 1,2,15,16,29,30with infusional 5-FU Bolus 400 mg/m2 IV bolus, d 1,2,15,16,29,305-FU/LV 5-FU Infusionb 600 mg/m2 IV over 22 h, d 1,2,15,16,29,30(next cycle Starting Dose & Modified Dose Levels (mg/m2)begins on

Starting Dose Dose Level -1 Dose Level -2day 43)

CAMPTOSAR 180 150 120LV 200 200 2005-FU Bolus 400 320 2405-FU Infusionb 600 480 360

a Dose reductions beyond dose level –2 by decrements of ≈20% may be warranted for patients continuing to experience toxicity. Provided intolerable toxicity doesnot develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit.

b Infusion follows bolus administration.

1�

Page 15: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Preparation & Administration PrecautionsAs with other potentially toxic anticancer agents, care should be exercised in

the handling and preparation of infusion solutions prepared from CAMPTOSARInjection. The use of gloves is recommended. If a solution of CAMPTOSAR con-tacts the skin, wash the skin immediately and thoroughly with soap and water. IfCAMPTOSAR contacts the mucous membranes, flush thoroughly with water.Several published guidelines for handling and disposal of anticancer agents areavailable.1-7

Preparation of Infusion SolutionInspect vial contents for particulate matter and repeat inspection when drug

product is withdrawn from vial into syringe.CAMPTOSAR Injection must be diluted prior to infusion. CAMPTOSAR should

be diluted in 5% Dextrose Injection, USP, (preferred) or 0.9% Sodium ChlorideInjection, USP, to a final concentration range of 0.12 to 2.8 mg/mL. In most clin-ical trials, CAMPTOSAR was administered in 250 mL to 500 mL of 5% DextroseInjection, USP.

The solution is physically and chemically stable for up to 24 hours at roomtemperature (approximately 25°C) and in ambient fluorescent lighting. Solutionsdiluted in 5% Dextrose Injection, USP, and stored at refrigerated temperatures(approximately 2° to 8°C), and protected from light are physically and chemicallystable for 48 hours. Refrigeration of admixtures using 0.9% Sodium ChlorideInjection, USP, is not recommended due to a low and sporadic incidence of visi-ble particulates. Freezing CAMPTOSAR and admixtures of CAMPTOSAR mayresult in precipitation of the drug and should be avoided. Becauseof possible microbial contamination during dilution, it is advisable to use theadmixture prepared with 5% Dextrose Injection, USP, within 24 hours if refriger-ated (2° to 8°C, 36° to 46°F). In the case of admixtures prepared with 5%Dextrose Injection, USP, or Sodium Chloride Injection, USP, the solutions shouldbe used within 6 hours if kept at room temperature (15° to 30°C, 59° to 86°F).

Other drugs should not be added to the infusion solution. Parenteral drugproducts should be inspected visually for particulate matter and discolorationprior to administration whenever solution and container permit.HOW SUPPLIED

Each mL of CAMPTOSAR Injection contains 20 mg irinotecan (on the basis of the trihydrate salt); 45 mg sorbitol; and 0.9 mg lactic acid. When necessary,pH has been adjusted to 3.5 (range, 3.0 to 3.8) with sodium hydroxide orhydrochloric acid.

CAMPTOSAR Injection is available in single-dose amber glass vials in the following package sizes:

2 mL NDC 0009-7529-025 mL NDC 0009-7529-01

This is packaged in a backing/plastic blister to protect against inadvertentbreakage and leakage. The vial should be inspected for damage and visible signsof leaks before removing the backing/plastic blister. If damaged, incinerate theunopened package.

Store at controlled room temperature 15° to 30°C (59° to 86°F). Protect fromlight. It is recommended that the vial (and backing/plastic blister) should remainin the carton until the time of use.

REFERENCES1. ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and

Recommendations for Practice. Pittsburgh, Pa: Oncology Nursing Society;1999:32-41.

2. Recommendations for the safe handling of parenteral antineoplastic drugs.Washington, DC: Division of Safety, National Institutes of Health; 1983. US Dept of Health and Human Services, Public Health Service publication NIH83-2621.

3. AMA Council on Scientific Affairs. Guidelines for handling parenteral antineo-plastics. JAMA. 1985;253:1590-1592.

4. National Study Commission on Cytotoxic Exposure. Recommendations forhandling cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman,National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue,Boston, MA 02115.

5. Clinical Oncological Society of Australia. Guidelines and recommendations forsafe handling of antineoplastic agents. Med J Australia. 1983;1:426-428.

6. Jones RB, Frank R, Mass T. Safe handling of chemotherapeutic agents: areport from the Mount Sinai Medical Center. CA-A Cancer J for Clin.1983;33:258-263.

7. American Society of Hospital Pharmacists. ASHP technical assistance bulletinon handling cytotoxic and hazardous drugs. Am J Hosp Pharm.1990;47:1033-1049.

8. Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice Guidelines.) Am J Health-SystPharm. 1996;53;1669-1685.

Camptosar brand of irinotecan hydrochloride injection

Licensed from Yakult Honsha Co., LTD, Japan, and Daiichi Pharmaceutical Co.,LTD, Japan

Revised June 2006LAB-0134-10.0

Camptosar®

irinotecan hydrochloride injectionCamptosar®

irinotecan hydrochloride injectionCamptosar®

irinotecan hydrochloride injection

Table 11. Recommended Dose Modifications for CAMPTOSAR/5-Fluorouracil (5-FU)/Leucovorin (LV) Combination Schedules

Patients should return to pre-treatment bowel function without requiring antidiarrhea medications for at least 24 hours before the next chemotherapy administra-tion. A new cycle of therapy should not begin until the granulocyte count has recovered to ≥1500/mm3, and the platelet count has recovered to ≥100,000/mm3, andtreatment-related diarrhea is fully resolved. Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities. If the patient hasnot recovered after a 2-week delay, consideration should be given to discontinuing therapy.

Neutropenia1 (1500 to 1999/mm3)2 (1000 to 1499/mm3)3 (500 to 999/mm3)4 (<500/mm3)

Maintain dose level↓ 1 dose level Omit dose until resolved to ≤ grade 2, then ↓ 1 dose level Omit dose until resolved to ≤ grade 2, then ↓ 2 dose levels

Maintain dose levelMaintain dose level↓ 1 dose level↓ 2 dose levels

Diarrhea1 (2-3 stools/day > pretxc)2 (4-6 stools/day > pretx)3 (7-9 stools/day > pretx)4 (≥10 stools/day > pretx)

Delay dose until resolved to baseline, then give same doseOmit dose until resolved to baseline, then ↓ 1 dose levelOmit dose until resolved to baseline, then ↓ 1 dose level Omit dose until resolved to baseline, then ↓ 2 dose levels

Maintain dose levelMaintain dose level↓ 1 dose level ↓ 2 dose levels

Other nonhematologic toxicitiesd

1234

Maintain dose levelOmit dose until resolved to ≤ grade 1, then ↓ 1 dose levelOmit dose until resolved to ≤ grade 2, then ↓ 1 dose level Omit dose until resolved to ≤ grade 2, then ↓ 2 dose levels

For mucositis/stomatitis decrease only 5-FU, not CAMPTOSAR

Maintain dose levelMaintain dose level↓ 1 dose level ↓ 2 dose levels

For mucositis/stomatitis decrease only 5-FU, not CAMPTOSAR

Toxicity NCI CTC Gradea (Value)

No toxicity

During a Cycle of Therapy

Maintain dose level

At the Start of SubsequentCycles of Therapyb

Maintain dose level

Other hematologic toxicities Dose modifications for leukopenia or thrombocytopenia during a cycle of therapy and at the start of subsequent cycles oftherapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.

Neutropenic fever Omit dose until resolved, then ↓ 2 dose levels

a National Cancer Institute Common Toxicity Criteria (version 1.0)b Relative to the starting dose used in the previous cyclec Pretreatmentd Excludes alopecia, anorexia, asthenia

Table 12. Single-Agent Regimens of CAMPTOSAR and Dose Modifications

Weekly Regimena 125 mg/m2 IV over 90 min, d 1,8,15,22 then 2-wk rest

Starting Dose & Modified Dose Levelsc (mg/m2)

Starting Dose Dose Level -1 Dose Level -2125 100 75

Once-Every-3-Week 350 mg/m2 IV over 90 min, once every 3 wksc

Regimenb

Starting Dose & Modified Dose Levels (mg/m2)

Starting Dose Dose Level -1 Dose Level -2350 300 250

a Subsequent doses may be adjusted as high as 150 mg/m2 or to as low as 50 mg/m2 in 25 to 50 mg/m2 decrements depending upon individual patient tolerance.b Subsequent doses may be adjusted as low as 200 mg/m2 in 50 mg/m2 decrements depending upon individual patient tolerance.c Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit.

Worst ToxicityNCI Gradeb (Value)

No toxicity

Neutropenia1 (1500 to 1999/mm3)2 (1000 to 1499/mm3)3 (500 to 999/mm3)4 (<500/mm3)

Neutropenic fever

Other hematologictoxicities

Diarrhea1 (2-3 stools/day > pretxc)2 (4-6 stools/day > pretx)3 (7-9 stools/day > pretx)4 (≥10 stools/day > pretx)

Other nonhematologicd

toxicities1234

Table 13. Recommended Dose Modifications For Single-Agent Schedules a

A new cycle of therapy should not begin until the granulocyte count has recovered to ≥1500/mm3, and the platelet count has recovered to ≥100,000/mm3, and treatment-related diarrhea is fully resolved. Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consideration should be given to discontinuing CAMPTOSAR.

During a Cycle of Therapy

Weekly

Maintain dose level

Maintain dose level↓ 25 mg/m2

Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m2

Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m2

Omit dose until resolved, then ↓ 50 mg/m2 when resolved

Maintain dose level↓ 25 mg/m2

Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m2

Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m2

Maintain dose level↓ 25 mg/m2

Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m2

Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m2

Weekly

↑ 25 mg/m2 up to a maximumdose of 150 mg/m2

Maintain dose levelMaintain dose level↓ 25 mg/m2

↓ 50 mg/m2

↓ 50 mg/m2

Maintain dose levelMaintain dose level↓ 25 mg/m2

↓ 50 mg/m2

Maintain dose level↓ 25 mg/m2

↓ 25 mg/m2

↓ 50 mg/m2

Once Every 3 Weeks

Maintain dose level

Maintain dose levelMaintain dose level↓ 50 mg/m2

↓ 50 mg/m2

↓ 50 mg/m2

Maintain dose levelMaintain dose level↓ 50 mg/m2

↓ 50 mg/m2

Maintain dose level↓ 50 mg/m2

↓ 50 mg/m2

↓ 50 mg/m2

Dose modifications for leukopenia, thrombocytopenia, and anemia during a cycle of therapy and at the start of subsequent cycles oftherapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.

At the Start of the Next Cycles of Therapy(After Adequate Recovery), Compared with the

Starting Dose in the Previous Cyclea

a All dose modifications should be based on the worst preceding toxicity b National Cancer Institute Common Toxicity Criteria (version 1.0)c Pretreatmentd Excludes alopecia, anorexia, asthenia

Pharmacia & Upjohn CoDivision of P�zer Inc, NY, NY 10017

Distributed by

1�

Page 16: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Camptosar® irinotecan hydrochloride injection

For Intravenous Use Only

WARNINGS CAMPTOSAR Injection should be administered only under the supervision of a

physician who is experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.CAMPTOSAR can induce both early and late forms of diarrhea that appear to be mediated by different mechanisms. Both forms of diarrhea may be severe. Early diarrhea (occurring during or shortly after infusion of CAMPTOSAR) may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Early diarrhea and other cholinergic symptoms may be prevented or ameliorated by atropine (see PRECAUTIONS, General). Late diarrhea (generally occurring more than 24 hours after administration of CAMPTOSAR) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Late diarrhea should be treated promptly with loperamide. Patients with diarrhea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated or antibiotic therapy if they develop ileus, fever, or severe neutropenia (see WARNINGS). Administration of CAMPTOSAR should be interrupted and subsequent doses reduced if severe diarrhea occurs (see DOSAGE AND ADMINISTRATION).

Severe myelosuppression may occur (see WARNINGS). DESCRIPTION CAMPTOSAR Injection (irinotecan hydrochloride injection) is an antineoplastic

agent of the topoisomerase I inhibitor class. Irinotecan hydrochloride was clinically investigated as CPT-11.

CAMPTOSAR is supplied as a sterile, pale yellow, clear, aqueous solution. It is available in two single-dose sizes: 2 mL-fill vials contain 40 mg irinotecan hydrochloride and 5 mL-fill vials contain 100 mg irinotecan hydrochloride. Each milliliter of solution contains 20 mg of irinotecan hydrochloride (on the basis of the trihydrate salt), 45 mg of sorbitol NF powder, and 0.9 mg of lactic acid, USP. The pH of the solution has been adjusted to 3.5 (range, 3.0 to 3.8) with sodium hydroxide or hydrochloric acid. CAMPTOSAR is intended for dilution with 5% Dextrose Injection, USP (D5W), or 0.9% Sodium Chloride Injection, USP, prior to intravenous infusion. The preferred diluent is 5% Dextrose Injection, USP.

Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extract from plants such as Camptotheca acuminata or is chemically synthesized. The chemical name is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano[3’,4’:6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4’bipiperidine]-1’-carboxylate, monohydrochloride, trihydrate. Its structural formula is as follows:

Page 17: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Irinotecan hydrochloride is a pale yellow to yellow crystalline powder, with the

empirical formula C33H38N4O6•HCl•3H2O and a molecular weight of 677.19. It is slightly soluble in water and organic solvents. CLINICAL PHARMACOLOGY

Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks.

Irinotecan serves as a water-soluble precursor of the lipophilic metabolite SN-38. SN-38 is formed from irinotecan by carboxylesterase-mediated cleavage of the carbamate bond between the camptothecin moiety and the dipiperidino side chain. SN-38 is approximately 1000 times as potent as irinotecan as an inhibitor of topoisomerase I purified from human and rodent tumor cell lines. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. However, the plasma area under the concentration versus time curve (AUC) values for SN-38 are 2% to 8% of irinotecan and SN-38 is 95% bound to plasma proteins compared to approximately 50% bound to plasma proteins for irinotecan (see Pharmacokinetics). The precise contribution of SN-38 to the activity of CAMPTOSAR is thus unknown. Both irinotecan and SN-38 exist in an active lactone form and an inactive hydroxy acid anion form. A pH-dependent equilibrium exists between the two forms such that an acid pH promotes the formation of the lactone, while a more basic pH favors the hydroxy acid anion form. Administration of irinotecan has resulted in antitumor activity in mice bearing cancers of rodent origin and in human carcinoma xenografts of various histological types. Pharmacokinetics

After intravenous infusion of irinotecan in humans, irinotecan plasma concentrations decline in a multiexponential manner, with a mean terminal elimination half-life of about 6 to 12 hours. The mean terminal elimination half-life of the active metabolite SN-38 is about 10 to 20 hours. The half-lives of the lactone (active) forms of irinotecan and SN-38 are similar to those of total irinotecan and SN-38, as the lactone and hydroxy acid forms are in equilibrium.

Over the recommended dose range of 50 to 350 mg/m2, the AUC of irinotecan

Page 18: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

increases linearly with dose; the AUC of SN-38 increases less than proportionally with dose. Maximum concentrations of the active metabolite SN-38 are generally seen within 1 hour following the end of a 90-minute infusion of irinotecan. Pharmacokinetic parameters for irinotecan and SN-38 following a 90-minute infusion of irinotecan at dose levels of 125 and 340 mg/m2 determined in two clinical studies in patients with solid tumors are summarized in Table 1:

Table 1.Summary of Mean (±Standard Deviation)

Irinotecan and SN-38 Pharmacokinetic Parameters in Patients with Solid Tumors

Irinotecan SN-38 Dose

(mg/m2) Cmax (ng/mL)

AUC0-24 (ng·h/mL)

t1/2 (h)

Vz (L/m2)

CL (L/h/m2)

Cmax (ng/mL)

AUC0-24 (ng·h/mL)

t1/2 (h)

125 (N=64)

1,660 ±797

10,200 ±3,270

5.8a

±0.7 110

±48.5 13.3

±6.01 26.3

±11.9 229

±108 10.4a

±3.1

340 (N=6)

3,392 ±874

20,604 ±6,027

11.7b

±1.0 234

±69.6 13.9 ±4.0

56.0 ±28.2

474 ±245

21.0b

±4.3

Cmax - Maximum plasma concentration AUC0-24 - Area under the plasma concentration-time curve from time

0 to 24 hours after the end of the 90-minute infusion t1/2 - Terminal elimination half-life Vz - Volume of distribution of terminal elimination phase CL - Total systemic clearance a Plasma specimens collected for 24 hours following the end of the 90-minute infusion. b Plasma specimens collected for 48 hours following the end of the 90-minute infusion. Because of the longer

collection period, these values provide a more accurate reflection of the terminal elimination half-lives of irinotecan and SN-38.

Irinotecan exhibits moderate plasma protein binding (30% to 68% bound). SN-38 is

highly bound to human plasma proteins (approximately 95% bound). The plasma protein to which irinotecan and SN-38 predominantly binds is albumin. Metabolism and Excretion: The metabolic conversion of irinotecan to the active metabolite SN-38 is mediated by carboxylesterase enzymes and primarily occurs in the liver. SN-38 is subsequently conjugated predominantly by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite. UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism. Approximately 10% of the North American population is homozygous for the UGT1A1*28 allele. In a prospective study, in which irinotecan was administered as a single-agent on a once-every-3-week schedule, patients who were homozygous for UGT1A1*28 had a higher exposure to SN-38 than patients with the wild-type UGT1A1 allele (See WARNINGS and DOSAGE AND ADMINISTRATION). SN-38 glucuronide had 1/50 to 1/100 the activity of SN-38 in cytotoxicity assays using two cell lines in vitro. The disposition of irinotecan has not been fully elucidated in humans. The urinary excretion of irinotecan is 11% to 20%; SN-38, <1%; and SN-38 glucuronide, 3%. The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following administration of irinotecan in two patients ranged from approximately 25% (100 mg/m2) to 50% (300 mg/m2). Pharmacokinetics in Special Populations

Page 19: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Geriatric: In studies using the weekly schedule, the terminal half-life of irinotecan was 6.0 hours in patients who were 65 years or older and 5.5 hours in patients younger than 65 years. Dose-normalized AUC0-24 for SN-38 in patients who were at least 65 years of age was 11% higher than in patients younger than 65 years. No change in the starting dose is recommended for geriatric patients receiving the weekly dosage schedule of irinotecan. The pharmacokinetics of irinotecan given once every 3 weeks has not been studied in the geriatric population; a lower starting dose is recommended in patients 70 years or older based on clinical toxicity experience with this schedule (see DOSAGE AND ADMINISTRATION). Pediatric: See Pediatric Use under PRECAUTIONS. Gender: The pharmacokinetics of irinotecan do not appear to be influenced by gender. Race: The influence of race on the pharmacokinetics of irinotecan has not been evaluated. Hepatic Insufficiency: Irinotecan clearance is diminished in patients with hepatic dysfunction while exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function. The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations. However, the tolerability of irinotecan in patients with hepatic dysfunction (bilirubin greater than 2 mg/dl) has not been assessed sufficiently, and no recommendations for dosing can be made (see DOSAGE AND ADMINISTRATION and PRECAUTIONS: Patients at Particular Risk Sections). Renal Insufficiency: The influence of renal insufficiency on the pharmacokinetics of irinotecan has not been evaluated. Therefore, caution should be undertaken in patients with impaired renal function. Irinotecan is not recommended for use in patients on dialysis. Drug-Drug Interactions

5-fluorouracil (5-FU) and leucovorin (LV): In a phase 1 clinical study involving irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in 26 patients with solid tumors, the disposition of irinotecan was not substantially altered when the drugs were co-administered. Although the Cmax and AUC0-24 of SN-38, the active metabolite, were reduced (by 14% and 8%, respectively) when irinotecan was followed by 5-FU and LV administration compared with when irinotecan was given alone, this sequence of administration was used in the combination trials and is recommended (see DOSAGE AND ADMINISTRATION). Formal in vivo or in vitro drug interaction studies to evaluate the influence of irinotecan on the disposition of 5-FU and LV have not been conducted.

Anticonvulsants: Exposure to irinotecan and its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital or carbamazepine. The appropriate starting dose for patients taking these anticonvulsants has not been formally defined. The following drugs are also CYP3A4 inducers: rifampin, rifabutin. For patients requiring anticonvulsant treatment, consideration should be given to substituting non-enzyme inducing anticonvulsants at least 2 weeks prior to initiation of irinotecan therapy. Dexamethasone does not appear to alter the pharmacokinetics of irinotecan.

Page 20: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

St. John’s Wort: St. John’s Wort is an inducer of CYP3A4 enzymes. Exposure to the active metabolite SN-38 is reduced in patients receiving concomitant St. John’s Wort. St. John’s Wort should be discontinued at least 2 weeks prior to the first cycle of irinotecan, and St. John’s Wort is contraindicated during irinotecan therapy.

Ketoconazole: Ketoconazole is a strong inhibitor of CYP3A4 enzymes. Patients receiving concomitant ketoconazole have increased exposure to irinotecan and its active metabolite SN-38. Patients should discontinue ketoconazole at least 1 week prior to starting irinotecan therapy and ketoconazole is contraindicated during irinotecan therapy.

Neuromuscular blocking agents. Interaction between irinotecan and neuromuscular blocking agents cannot be ruled out. Irinotecan has anticholinesterase activity, which may prolong the neuromuscular blocking effects of suxamethonium and the neuromuscular blockade of non-depolarizing drugs may be antagonized.

Atazanavir sulfate: Coadministration of atazanavir sulfate, a CYP3A4 and UGT1A1 inhibitor has the potential to increase systemic exposure to SN-38, the active metabolite of irinotecan. Physicians should take this into consideration when co-administering these drugs.

CLINICAL STUDIES

Irinotecan has been studied in clinical trials in combination with 5-fluorouracil (5-FU) and leucovorin (LV) and as a single agent (see DOSAGE AND ADMINISTRATION). When given as a component of combination-agent treatment, irinotecan was either given with a weekly schedule of bolus 5-FU/LV or with an every-2-week schedule of infusional 5-FU/LV. Weekly and a once-every-3-week dosage schedules were used for the single-agent irinotecan studies. Clinical studies of combination and single-agent use are described below. First-Line Therapy in Combination with 5-FU/LV for the Treatment of Metastatic Colorectal Cancer

Two phase 3, randomized, controlled, multinational clinical trials support the use of CAMPTOSAR Injection as first-line treatment of patients with metastatic carcinoma of the colon or rectum. In each study, combinations of irinotecan with 5-FU and LV were compared with 5-FU and LV alone. Study 1 compared combination irinotecan/bolus 5-FU/LV therapy given weekly with a standard bolus regimen of 5-FU/LV alone given daily for 5 days every 4 weeks; an irinotecan-alone treatment arm given on a weekly schedule was also included. Study 2 evaluated two different methods of administering infusional 5-FU/LV, with or without irinotecan. In both studies, concomitant medications such as antiemetics, atropine, and loperamide were given to patients for prophylaxis and/or management of symptoms from treatment. In Study 2, a 7-day course of fluoroquinolone antibiotic prophylaxis was given in patients whose diarrhea persisted for greater than 24 hours despite loperamide or if they developed a fever in addition to diarrhea. Treatment with oral fluoroquinolone was also initiated in patients who developed an absolute neutrophil count (ANC) <500/mm3, even in the absence of fever or diarrhea. Patients in both studies also received treatment with intravenous antibiotics if they had persistent diarrhea or fever or if ileus developed. In both studies, the combination of irinotecan/5-FU/LV therapy resulted in significant

Page 21: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

improvements in objective tumor response rates, time to tumor progression, and survival when compared with 5-FU/LV alone. These differences in survival were observed in spite of second-line therapy in a majority of patients on both arms, including crossover to irinotecan-containing regimens in the control arm. Patient characteristics and major efficacy results are shown in Table 2.

Table 2. Combination Dosage Schedule: Study Results Study 1 Study 2 Irinotecan + Bolus 5-FU/LV Bolus 5-FU/LV Irinotecan Irinotecan + weekly x 4 q daily x 5 q weekly x 4 q Infusional Infusional 6 weeks 4 weeks 6 weeks 5-FU/LV 5-FU/LV Number of Patients 231 226 226 198 187 Demographics and Treatment Administration Female/Male (%) 34/65 45/54 35/64 33/67 47/53 Median Age in years (range) 62 (25-85) 61 (19-85) 61 (30-87) 62 (27-75) 59 (24-75)

39 41 46 51 51 46 45 46 42 41

Performance Status (%) 0 1 2 15 13 8 7 8

81 85 84 55 65

Primary Tumor (%) Colon Rectum 17 14 15 45 35

1.9 1.7 1.8 4.5 2.7

Median Time from Diagnosis to Randomization (months, range) (0-161) (0-203) (0.1-185) (0-88) (0-104)

89 92 90 74 76

Prior Adjuvant 5-FU Therapy (%) No Yes 11 8 10 26 24

Median Duration of Study Treatmenta (months) 5.5 4.1 3.9 5.6 4.5

72 — 75 87 —

Median Relative Dose Intensity (%)a

Irinotecan 5-FU 71 86 — 86 93

Efficacy Results 39 21 18 35 22 Confirmed Objective Tumor

Response Rateb (%) (p<0.0001)c (p<0.005)c

7.0 4.3 4.2 6.7 4.4 Median Time to Tumor Progressiond

(months) (p=0.004)d (p<0.001)d 14.8 12.6 12.0 17.4 14.1 Median Survival

(months) (p<0.05)d (p<0.05)d a Study 1: N=225 (irinotecan/5-FU/LV),N=219 (5-FU/LV),N=223 (irinotecan) Study 2: N=199 (irinotecan/5-FU/LV),N=186 (5-FU/LV) b Confirmed > 4 to 6 weeks after first evidence of objective response c Chi-square test d Log-rank test Improvement was noted with irinotecan-based combination therapy relative to 5-FU/LV when response rates and time to tumor progression were examined across the following demographic and disease-related subgroups (age, gender, ethnic origin, performance status, extent of organ involvement with cancer, time from diagnosis of cancer, prior adjuvant therapy, and baseline laboratory abnormalities). Figures 1 and 2 illustrate the Kaplan-Meier survival curves for the comparison of irinotecan/5-FU/LV versus 5-FU/LV in Studies 1 and 2, respectively.

Page 22: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Figure 1. Survival First-Line Irinotecan/5-FU/LV vs 5-FU/LV

Study 1

0.00.10.20.30.40.50.60.70.80.91.0

0 3 6 9 12 15 18 21 24 27 30 33 36 39 42Months

Prob

abili

ty

p<0.05*

*log-rank test

Irinotecan/5-FU/LV

5-FU/LV

Page 23: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Second-Line Treatment for Recurrent or Progressive Metastatic Colorectal Cancer After 5-FU-Based Treatment Weekly Dosage Schedule

Data from three open-label, single-agent, clinical studies, involving a total of 304 patients in 59 centers, support the use of CAMPTOSAR in the treatment of patients with metastatic cancer of the colon or rectum that has recurred or progressed following treatment with 5-FU-based therapy. These studies were designed to

Figure 2. Survival First-Line Irinotecan/5-FU/LV vs 5-FU/LV

Study 2

0.00.10.20.30.40.50.60.70.80.91.0

0 3 6 9 12 15 18 21 24 27 30Months

Prob

abili

ty

p<0.05*

*log-rank test

Irinotecan/5-FU/LV

5-FU/LV

Page 24: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

evaluate tumor response rate and do not provide information on actual clinical benefit, such as effects on survival and disease-related symptoms. In each study, CAMPTOSAR was administered in repeated 6-week cycles consisting of a 90-minute intravenous infusion once weekly for 4 weeks, followed by a 2-week rest period. Starting doses of CAMPTOSAR in these trials were 100, 125, or 150 mg/m2,but the 150-mg/m2 dose was poorly tolerated (due to unacceptably high rates of grade 4 late diarrhea and febrile neutropenia). Study 1 enrolled 48 patients and was conducted by a single investigator at several regional hospitals. Study 2 was a multicenter study conducted by the North Central Cancer Treatment Group. All 90 patients enrolled in Study 2 received a starting dose of 125 mg/m2. Study 3 was a multicenter study that enrolled 166 patients from 30 institutions. The initial dose in Study 3 was 125 mg/m2 but was reduced to 100 mg/m2 because the toxicity seen at the 125-mg/m2 dose was perceived to be greater than that seen in previous studies. All patients in these studies had metastatic colorectal cancer, and the majority had disease that recurred or progressed following a 5-FU-based regimen administered for metastatic disease. The results of the individual studies are shown in Table 3.

Page 25: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Table 3. Weekly Dosage Schedule: Study Results

Study 1 2 3 Number of Patients 48 90 64 102 Starting Dose (mg/m2/wk x 4) 125a 125 125 100 Demographics and Treatment Administration Female/Male (%) 46/54 36/64 50/50 51/49 Median Age in years (range) 63 (29-78) 63 (32-81) 61 (42-84) 64 (25-84) Ethnic Origin (%) White African American Hispanic Oriental/Asian

79 12 8 0

96 4 0 0

81 11 8 0

91 5 2 2

Performance Status (%) 0

60

38

59

44

1 38 48 33 51 2 2 14 8 5 Primary Tumor (%) Colon Rectum Unknown

100

0 0

71 29 0

89 11 0

87 8 5

Prior 5-FU Therapy (%) For Metastatic Disease ≤ 6 months after Adjuvant > 6 months after Adjuvant Classification Unknown

81 15 2 2

66 7

16 12

73 27 0 0

68 28 2 3

Prior Pelvic/Abdominal Irradiation (%) Yes Other None

3 0

97

29 9

62

0 2

98

0 4

96 Duration of Treatment with CAMPTOSAR (median, months)

5

4

4

3

Relative Dose Intensityb (median %) 74 67 73 81 Efficacy Confirmed Objective Response Rate (%)c

(95% CI) 21

(9.3 - 32.3) 13

(6.3 - 20.4) 14

(5.5 - 22.6) 9

(3.3 - 14.3) Time to Response (median, months) 2.6 1.5 2.8 2.8 Response Duration (median, months) 6.4 5.9 5.6 6.4 Survival (median, months) 10.4 8.1 10.7 9.3 1-Year Survival (%) 46 31 45 43 a Nine patients received 150 mg/m2 as a starting dose; two (22.2%) responded to CAMPTOSAR. b Relative dose intensity for CAMPTOSAR based on planned dose intensity of 100, 83.3, and

66.7 mg/m2/wk corresponding with 150, 125, and 100 mg/m2 starting doses, respectively. c Confirmed ≥ 4 to 6 weeks after first evidence of objective response.

Page 26: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

In the intent-to-treat analysis of the pooled data across all three studies, 193 of the 304

patients began therapy at the recommended starting dose of 125 mg/m2. Among these 193 patients, 2 complete and 27 partial responses were observed, for an overall response rate of 15.0% (95% Confidence Interval [CI], 10.0% to 20.1%) at this starting dose. A considerably lower response rate was seen with a starting dose of 100 mg/m2. The majority of responses were observed within the first two cycles of therapy, but responses did occur in later cycles of treatment (one response was observed after the eighth cycle). The median response duration for patients beginning therapy at 125 mg/m2 was 5.8 months (range, 2.6 to 15.1 months). Of the 304 patients treated in the three studies, response rates to CAMPTOSAR were similar in males and females and among patients older and younger than 65 years. Rates were also similar in patients with cancer of the colon or cancer of the rectum and in patients with single and multiple metastatic sites. The response rate was 18.5% in patients with a performance status of 0 and 8.2% in patients with a performance status of 1 or 2. Patients with a performance status of 3 or 4 have not been studied. Over half of the patients responding to CAMPTOSAR had not responded to prior 5-FU. Patients who had received previous irradiation to the pelvis responded to CAMPTOSAR at approximately the same rate as those who had not previously received irradiation. Once-Every-3-Week Dosage Schedule Single-Arm Studies: Data from an open-label, single-agent, single-arm, multicenter, clinical study involving a total of 132 patients support a once every-3-week dosage schedule of irinotecan in the treatment of patients with metastatic cancer of the colon or rectum that recurred or progressed following treatment with 5-FU. Patients received a starting dose of 350 mg/m2 given by 30-minute intravenous infusion once every 3 weeks. Among the 132 previously treated patients in this trial, the intent-to-treat response rate was 12.1% (95% CI, 7.0% to 18.1%). Randomized Trials: Two multicenter, randomized, clinical studies further support the use of irinotecan given by the once-every-3-week dosage schedule in patients with metastatic colorectal cancer whose disease has recurred or progressed following prior 5-FU therapy. In the first study, second-line irinotecan therapy plus best supportive care was compared with best supportive care alone. In the second study, second-line irinotecan therapy was compared with infusional 5-FU-based therapy. In both studies, irinotecan was administered intravenously at a starting dose of 350 mg/m2 over 90 minutes once every 3 weeks. The starting dose was 300 mg/m2 for patients who were 70 years and older or who had a performance status of 2. The highest total dose permitted was 700 mg. Dose reductions and/or administration delays were permitted in the event of severe hematologic and/or nonhematologic toxicities while on treatment. Best supportive care was provided to patients in both arms of Study 1 and included antibiotics, analgesics, corticosteroids, transfusions, psychotherapy, or any other symptomatic therapy as clinically indicated. In both studies, concomitant medications such as antiemetics, atropine, and loperamide were given to patients for prophylaxis and/or management of symptoms from treatment. If late diarrhea persisted for greater than 24 hours despite loperamide, a 7-day course of fluoroquinolone antibiotic prophylaxis was given. Patients in the control arm of the second study received one of the following 5-FU regimens: (1)

Page 27: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

LV, 200 mg/m2 IV over 2 hours; followed by 5-FU, 400 mg/m2 IV bolus; followed by 5-FU, 600 mg/m2 continuous IV infusion over 22 hours on days 1 and 2 every 2 weeks; (2) 5-FU, 250 to 300 mg/m2/day protracted continuous IV infusion until toxicity; (3) 5-FU, 2.6 to 3 g/m2 IV over 24 hours every week for 6 weeks with or without LV, 20 to 500 mg/m2/day every week IV for 6 weeks with 2-week rest between cycles. Patients were to be followed every 3 to 6 weeks for 1 year.

A total of 535 patients were randomized in the two studies at 94 centers. The primary endpoint in both studies was survival. The studies demonstrated a significant overall survival advantage for irinotecan compared with best supportive care (p=0.0001) and infusional 5-FU-based therapy (p=0.035) as shown in Figures 3 and 4. In Study 1, median survival for patients treated with irinotecan was 9.2 months compared with 6.5 months for patients receiving best supportive care. In Study 2, median survival for patients treated with irinotecan was 10.8 months compared with 8.5 months for patients receiving infusional 5-FU-based therapy. Multiple regression analyses determined that patients’ baseline characteristics also had a significant effect on survival. When adjusted for performance status and other baseline prognostic factors, survival among patients treated with irinotecan remained significantly longer than in the control populations (p=0.001 for Study 1 and p=0.017 for Study 2). Measurements of pain, performance status, and weight loss were collected prospectively in the two studies; however, the plan for the analysis of these data was defined retrospectively. When comparing irinotecan with best supportive care in Study 1, this analysis showed a statistically significant advantage for irinotecan, with longer time to development of pain (6.9 months versus 2.0 months), time to performance status deterioration (5.7 months versus 3.3 months), and time to > 5% weight loss (6.4 months versus 4.2 months). Additionally, 33.3% (33/99) of patients with a baseline performance status of 1 or 2 showed an improvement in performance status when treated with irinotecan versus 11.3% (7/62) of patients receiving best supportive care (p=0.002). Because of the inclusion of patients with non-measurable disease, intent-to-treat response rates could not be assessed.

Page 28: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Figure 3. Survival Second-Line Irinotecan vs Best Supportive Care (BSC)

Study 1

0.00.10.20.30.40.50.60.70.80.91.0

0 3 6 9 12 15 18 21Months

Prob

abili

ty

p=0.0001*

*log-rank test

Irinotecan

BSC

Irinotecan BSCN 189 90Median follow-up 13 moMedian (mo) 9.2 6.5

Figure 4. Survival Second-Line Irinotecan vs Infusional 5-FU

Study 2

0.00.10.20.30.40.50.60.70.80.91.0

0 3 6 9 12 15 18 21Months

Prob

abili

ty

p=0.035*

*log-rank test

Irinotecan

5-FU

Irinotecan 5-FUN 127 129Median follow-up 15 moMedian (mo) 10.8 8.5

Page 29: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

In the two randomized studies, the EORTC QLQ-C30 instrument was utilized. At the

start of each cycle of therapy, patients completed a questionnaire consisting of 30 questions, such as “Did pain interfere with daily activities?” (1 = Not at All, to 4 = Very Much) and “Do you have any trouble taking a long walk?” (Yes or No). The answers from the 30 questions were converted into 15 subscales, that were scored from 0 to 100, and the global health status subscale that was derived from two questions about the patient’s sense of general well being in the past week. In addition to the global health status subscale, there were five functional (i.e., cognitive, emotional, social, physical, role) and nine symptom (i.e., fatigue, appetite loss, pain assessment, insomnia, constipation, dyspnea, nausea/vomiting, financial impact, diarrhea) subscales. The results as summarized in Table 5 are based on patients’ worst post-baseline scores. In Study 1, a multivariate analysis and univariate analyses of the individual subscales were performed and corrected for multivariate testing. Patients receiving irinotecan reported significantly better results for the global health status, on two of five functional subscales, and on four of nine symptom subscales. As expected, patients receiving irinotecan noted significantly more diarrhea than those receiving best supportive care. In Study 2, the multivariate analysis on all 15 subscales did not indicate a statistically significant difference between irinotecan and infusional 5-FU.

Page 30: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Table 4. Once-Every-3-Week Dosage Schedule: Study Results

Study 1 Study 2 Irinotecan BSCa Irinotecan 5-FU Number of Patients 189 90 127 129 Demographics and Treatment Administration Female/Male (%) 32/68 42/58 43/57 35/65 Median Age in years (range) 59 (22-75) 62 (34-75) 58 (30-75) 58 (25-75) Performance Status (%) 0 47 31 58 54 1 39 46 35 43 2 14 23 8 3 Primary Tumor (%) Colon Rectum

55 45

52 48

57 43

62 38

Prior 5-FU Therapy (%) For Metastatic Disease As Adjuvant Treatment

70 30

63 37

58 42

68 32

Prior Irradiation (%) 26 27 18 20 Duration of Study Treatment (median, months) (Log-rank test)

4.1 -- 4.2 (p=0.02)

2.8

Relative Dose Intensity (median %)b 94 -- 95 81-99 Survival Survival (median, months) (Log-rank test)

9.2 (p=0.0001)

6.5 10.8 (p=0.035)

8.5

a BSC = best supportive care b Relative dose intensity for irinotecan based on planned dose intensity of 116.7 and 100 mg/m2/wk corresponding with 350 and 300 mg/m2 starting doses, respectively.

Page 31: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Table 5. EORTC QLQ-C30: Mean Worst Post-Baseline Scorea

QLQ-C30 Subscale Study 1 Study 2 Irinotecan BSC p-value Irinotecan 5-FU p-value Global Health Status 47 37 0.03 53 52 0.9

Functional Scales Cognitive 77 68 0.07 79 83 0.9 Emotional 68 64 0.4 64 68 0.9 Social 58 47 0.06 65 67 0.9 Physical 60 40 0.0003 66 66 0.9 Role 53 35 0.02 54 57 0.9 Symptom Scales Fatigue 51 63 0.03 47 46 0.9 Appetite Loss 37 57 0.0007 35 38 0.9 Pain Assessment 41 56 0.009 38 34 0.9 Insomnia 39 47 0.3 39 33 0.9 Constipation 28 41 0.03 25 19 0.9 Dyspnea 31 40 0.2 25 24 0.9 Nausea/Vomiting 27 29 0.5 25 16 0.09 Financial Impact 22 26 0.5 24 15 0.3 Diarrhea 32 19 0.01 32 22 0.2 a For the five functional subscales and global health status subscale, higher scores imply better functioning, whereas, on the nine symptom subscales, higher scores imply more severe symptoms. The subscale scores of each patient were collected at each visit until the patient dropped out of the study. INDICATIONS AND USAGE

CAMPTOSAR Injection is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. CAMPTOSAR is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. CONTRAINDICATIONS

CAMPTOSAR Injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. WARNINGS General

Outside of a well-designed clinical study, CAMPTOSAR Injection should not be used in combination with the “Mayo Clinic” regimen of 5-FU/LV (administration for 4-5 consecutive days every 4 weeks) because of reports of increased toxicity, including toxic deaths. CAMPTOSAR should be used as recommended (see DOSAGE AND ADMINISTRATION, Table 10).

In patients receiving either irinotecan/5-FU/LV or 5-FU/LV in the clinical trials, higher rates of hospitalization, neutropenic fever, thromboembolism, first-cycle treatment discontinuation, and early deaths were observed in patients with a baseline performance status of 2 than in patients with a baseline performance status of 0 or 1. Diarrhea

CAMPTOSAR can induce both early and late forms of diarrhea that appear to be mediated by different mechanisms. Early diarrhea (occurring during or shortly after infusion of CAMPTOSAR) is cholinergic in nature. It is usually transient and only infrequently is severe. It may be accompanied by symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that

Page 32: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

can cause abdominal cramping. Early diarrhea and other cholinergic symptoms may be prevented or ameliorated by administration of atropine (see PRECAUTIONS, General, for dosing recommendations for atropine).

Late diarrhea (generally occurring more than 24 hours after administration of CAMPTOSAR) can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis. Late diarrhea should be treated promptly with loperamide (see PRECAUTIONS, Information for Patients, for dosing recommendations for loperamide). Patients with diarrhea should be carefully monitored, should be given fluid and electrolyte replacement if they become dehydrated, and should be given antibiotic support if they develop ileus, fever, or severe neutropenia. After the first treatment, subsequent weekly chemotherapy treatments should be delayed in patients until return of pretreatment bowel function for at least 24 hours without need for anti-diarrhea medication. If grade 2, 3, or 4 late diarrhea occurs subsequent doses of CAMPTOSAR should be decreased within the current cycle (see DOSAGE AND ADMINISTRATION). Neutropenia

Deaths due to sepsis following severe neutropenia have been reported in patients treated with CAMPTOSAR. Neutropenic complications should be managed promptly with antibiotic support (see PRECAUTIONS). Therapy with CAMPTOSAR should be temporarily omitted during a cycle of therapy if neutropenic fever occurs or if the absolute neutrophil count drops <1000/mm3. After the patient recovers to an absolute neutrophil count ≥1000/mm3, subsequent doses of CAMPTOSAR should be reduced depending upon the level of neutropenia observed (see DOSAGE AND ADMINISTRATION).

Routine administration of a colony-stimulating factor (CSF) is not necessary, but physicians may wish to consider CSF use in individual patients experiencing significant neutropenia. Patients with Reduced UGT1A1 Activity

Individuals who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia following initiation of CAMPTOSAR treatment. A reduced initial dose should be considered for patients known to be homozygous for the UGT1A1*28 allele (see DOSAGE AND ADMINISTRATION). Heterozygous patients (carriers of one variant allele and one wild-type allele which results in intermediate UGT1A1 activity) may be at increased risk for neutropenia; however, clinical results have been variable and such patients have been shown to tolerate normal starting doses. Hypersensitivity

Hypersensitivity reactions including severe anaphylactic or anaphylactoid reactions have been observed. Colitis/Ileus

Cases of colitis complicated by ulceration, bleeding, ileus, and infection have been observed. Patients experiencing ileus should receive prompt antibiotic support (see PRECAUTIONS). Renal Impairment/Renal Failure

Rare cases of renal impairment and acute renal failure have been identified, usually in patients who became volume depleted from severe vomiting and/or diarrhea. Thromboembolism

Page 33: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Thromboembolic events have been observed in patients receiving irinotecan-containing regimens; the specific cause of these events has not been determined. Pregnancy

CAMPTOSAR may cause fetal harm when administered to a pregnant woman. Radioactivity related to 14C-irinotecan crosses the placenta of rats following intravenous administration of 10 mg/kg (which in separate studies produced an irinotecan Cmax and AUC about 3 and 0.5 times, respectively, the corresponding values in patients administered 125 mg/m2). Administration of 6 mg/kg/day intravenous irinotecan to rats (which in separate studies produced an irinotecan Cmax and AUC about 2 and 0.2 times, respectively, the corresponding values in patients administered 125 mg/m2) and rabbits (about one-half the recommended human weekly starting dose on a mg/m2 basis) during the period of organogenesis, is embryotoxic as characterized by increased post-implantation loss and decreased numbers of live fetuses. Irinotecan was teratogenic in rats at doses greater than 1.2 mg/kg/day (which in separate studies produced an irinotecan Cmax and AUC about 2/3 and 1/40th, respectively, of the corresponding values in patients administered 125 mg/m2) and in rabbits at 6.0 mg/kg/day (about one-half the recommended human weekly starting dose on a mg/m2 basis). Teratogenic effects included a variety of external, visceral, and skeletal abnormalities. Irinotecan administered to rat dams for the period following organogenesis through weaning at doses of 6 mg/kg/day caused decreased learning ability and decreased female body weights in the offspring. There are no adequate and well-controlled studies of irinotecan in pregnant women. If the drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with CAMPTOSAR. PRECAUTIONS General Care of Intravenous Site: CAMPTOSAR Injection is administered by intravenous infusion. Care should be taken to avoid extravasation, and the infusion site should be monitored for signs of inflammation. Should extravasation occur, flushing the site with sterile water and applications of ice are recommended. Premedication with Antiemetics: Irinotecan is emetigenic. It is recommended that patients receive premedication with antiemetic agents. In clinical studies of the weekly dosage schedule, the majority of patients received 10 mg of dexamethasone given in conjunction with another type of antiemetic agent, such as a 5-HT3 blocker (e.g., ondansetron or granisetron). Antiemetic agents should be given on the day of treatment, starting at least 30 minutes before administration of CAMPTOSAR. Physicians should also consider providing patients with an antiemetic regimen (e.g., prochlorperazine) for subsequent use as needed. Treatment of Cholinergic Symptoms: Prophylactic or therapeutic administration of 0.25 to 1 mg of intravenous or subcutaneous atropine should be considered (unless clinically contraindicated) in patients experiencing rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, abdominal cramping, or diarrhea (occurring during or shortly after infusion of CAMPTOSAR). These symptoms are expected to occur more frequently with higher irinotecan doses.

Page 34: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Immunosuppressant Effects/Increased Susceptibility to Infections: Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including CAMPTOSAR, may result in serious or fatal infections. Vaccination with a live vaccine should be avoided in patients receiving irinotecan. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished. Patients at Particular Risk: In patients receiving either irinotecan/5-FU/LV or 5-FU/LV in the clinical trials, higher rates of hospitalization, neutropenic fever, thromboembolism, first-cycle treatment discontinuation, and early deaths were observed in patients with a baseline performance status of 2 than in patients with a baseline performance status of 0 or 1. Patients who had previously received pelvic/abdominal radiation and elderly patients with comorbid conditions should be closely monitored.

The use of CAMPTOSAR in patients with significant hepatic dysfunction has not been established. In clinical trials of either dosing schedule, irinotecan was not administered to patients with serum bilirubin >2.0 mg/dL, or transaminase >3 times the upper limit of normal if no liver metastasis, or transaminase >5 times the upper limit of normal with liver metastasis. In clinical trials of the weekly dosage schedule, patients with modestly elevated baseline serum total bilirubin levels (1.0 to 2.0 mg/dL) had a significantly greater likelihood of experiencing first-cycle, grade 3 or 4 neutropenia than those with bilirubin levels that were less than 1.0 mg/dL (50% [19/38] versus 18% [47/226]; p<0.001). (Also see CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations: Hepatic Insufficiency). Patients with deficient glucuronidation of bilirubin, such as those with Gilbert’s syndrome, may be at greater risk of myelosuppression when receiving therapy with CAMPTOSAR.

Ketoconazole, enzyme-inducing anticonvulsants and St. John’s Wort are known to have drug-drug interactions with irinotecan therapy. (See Drug-Drug Interactions sub-section under CLINICAL PHARMACOLOGY)

Irinotecan commonly causes neutropenia, leucopenia, and anemia, any of which may be severe and therefore should not be used in patients with severe bone marrow failure. Patients must not be treated with irinotecan until resolution of the bowel obstruction. Patients with hereditary fructose intolerance should not be given CAMPTOSAR, as this product contains sorbitol. Information for Patients

Patients and patients’ caregivers should be informed of the expected toxic effects of CAMPTOSAR, particularly of its gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection. Each patient should be instructed to have loperamide readily available and to begin treatment for late diarrhea (generally occurring more than 24 hours after administration of CAMPTOSAR) at the first episode of poorly formed or loose stools or the earliest onset of bowel movements more frequent than normally expected for the patient. One dosage regimen for loperamide used in clinical trials consisted of the following (Note: This dosage regimen exceeds the usual dosage recommendations for loperamide.): 4 mg at the first onset of late diarrhea and then 2 mg every 2 hours until the patient is diarrhea-free for at least 12 hours. Loperamide is not recommended to be used for more than 48 consecutive hours at these doses, because of the risk of paralytic ileus. During the night, the patient may take 4 mg of loperamide every 4 hours. Premedication with loperamide is not recommended. The

Page 35: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

use of drugs with laxative properties should be avoided because of the potential for exacerbation of diarrhea. Patients should be advised to contact their physician to discuss any laxative use.

Patients should be instructed to contact their physician or nurse if any of the following occur: diarrhea for the first time during treatment; black or bloody stools; symptoms of dehydration such as lightheadedness, dizziness, or faintness; inability to take fluids by mouth due to nausea or vomiting; inability to get diarrhea under control within 24 hours; or fever or evidence of infection.

Patients should be warned about the potential for dizziness or visual disturbances which may occur within 24 hours following the administration of CAMPTOSAR, and advised not to drive or operate machinery if these symptoms occur.

Patients should be alerted to the possibility of alopecia. Laboratory Tests

Careful monitoring of the white blood cell count with differential, hemoglobin, and platelet count is recommended before each dose of CAMPTOSAR. Drug Interactions

The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.

Patients who have previously received pelvic/ abdominal irradiation are at increased risk of severe myelosuppression following the administration of CAMPTOSAR. The concurrent administration of CAMPTOSAR with irradiation has not been adequately studied and is not recommended.

Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect. However, serious opportunistic infections have not been observed, and no complications have specifically been attributed to lymphocytopenia.

Hyperglycemia has also been reported in patients receiving CAMPTOSAR. Usually, this has been observed in patients with a history of diabetes mellitus or evidence of glucose intolerance prior to administration of CAMPTOSAR. It is probable that dexamethasone, given as antiemetic prophylaxis, contributed to hyperglycemia in some patients.

The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients). The 8.5% incidence of akathisia, however, is within the range reported for use of prochlorperazine when given as a premedication for other chemotherapies.

It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.

In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.

Drug-Laboratory Test Interactions

There are no known interactions between CAMPTOSAR and laboratory tests.

Page 36: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Carcinogenesis, Mutagenesis & Impairment of Fertility Long-term carcinogenicity studies with irinotecan were not conducted. Rats were,

however, administered intravenous doses of 2 mg/kg or 25 mg/kg irinotecan once per week for 13 weeks (in separate studies, the 25 mg/kg dose produced an irinotecan Cmax and AUC that were about 7.0 times and 1.3 times the respective values in patients administered 125 mg/m2 weekly) and were then allowed to recover for 91 weeks. Under these conditions, there was a significant linear trend with dose for the incidence of combined uterine horn endometrial stromal polyps and endometrial stromal sarcomas. Neither irinotecan nor SN-38 was mutagenic in the in vitro Ames assay. Irinotecan was clastogenic both in vitro (chromosome aberrations in Chinese hamster ovary cells) and in vivo (micronucleus test in mice). No significant adverse effects on fertility and general reproductive performance were observed after intravenous administration of irinotecan in doses of up to 6 mg/kg/day to rats and rabbits. However, atrophy of male reproductive organs was observed after multiple daily irinotecan doses both in rodents at 20 mg/kg (which in separate studies produced an irinotecan Cmax and AUC about 5 and 1 times, respectively, the corresponding values in patients administered 125 mg/m2 weekly) and dogs at 0.4 mg/kg (which in separate studies produced an irinotecan Cmax and AUC about one-half and 1/15th, respectively, the corresponding values in patients administered 125 mg/m2 weekly). Pregnancy

Pregnancy Category D—see WARNINGS. Nursing Mothers

Radioactivity appeared in rat milk within 5 minutes of intravenous administration of radiolabeled irinotecan and was concentrated up to 65-fold at 4 hours after administration relative to plasma concentrations. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, it is recommended that nursing be discontinued when receiving therapy with CAMPTOSAR. Pediatric Use

The effectiveness of irinotecan in pediatric patients has not been established. Results from two open-label, single arm studies were evaluated. One hundred and seventy children with refractory solid tumors were enrolled in one phase 2 trial in which 50 mg/ m2 of irinotecan was infused for 5 consecutive days every 3 weeks. Grade 3-4 neutropenia was experienced by 54 (31.8%) patients. Neutropenia was complicated by fever in 15 (8.8%) patients. Grade 3-4 diarrhea was observed in 35 (20.6%) patients. This adverse event profile was comparable to that observed in adults. In the second phase 2 trial of 21 children with previously untreated rhabdomyosarcoma, 20 mg/m2 of irinotecan was infused for 5 consecutive days on weeks 0, 1, 3 and 4. This single agent therapy was followed by multimodal therapy. Accrual to the single agent irinotecan phase was halted due to the high rate (28.6%) of progressive disease and the early deaths (14%). The adverse event profile was different in this study from that observed in adults; the most significant grade 3 or 4 adverse events were dehydration experienced by 6 patients (28.6%) associated with severe hypokalemia in 5 patients (23.8%) and hyponatremia in 3 patients (14.3%); in addition Grade 3-4 infection was reported in 5 patients (23.8%) (across all courses of therapy and irrespective of causal relationship). Pharmacokinetic parameters for irinotecan and SN-38 were determined in 2 pediatric

Page 37: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

solid-tumor trials at dose levels of 50 mg/m2 (60-min infusion, n=48) and 125 mg/m2

(90-min infusion, n=6). Irinotecan clearance (mean ± S.D.) was 17.3 ± 6.7 L/h/m2 for the 50mg/m2 dose and 16.2 ± 4.6 L/h/m2 for the 125 mg/m2 dose, which is comparable to that in adults. Dose-normalized SN-38 AUC values were comparable between adults and children. Minimal accumulation of irinotecan and SN-38 was observed in children on daily dosing regimens [daily x 5 every 3 weeks or (daily x 5) x 2 weeks every 3 weeks]. Geriatric Use

Patients greater than 65 years of age should be closely monitored because of a greater risk of late diarrhea in this population (see CLINICAL PHARMACOLOGY, Pharmacokinetics in Special Populations and ADVERSE REACTIONS, Overview of Adverse Events). The starting dose of CAMPTOSAR in pat ients 70 years and older for the once-every-3-week-dosage schedule should be 300 mg/m2 (see DOSAGE AND ADMINISTRATION). ADVERSE REACTIONS First-Line Combination Therapy A total of 955 patients with metastatic colorectal cancer received the recommended regimens of irinotecan in combinat ion wi th 5-FU/LV, 5-FU/LV alone, or i r inotecan alone. In the two phase 3 s tudies , 370 pat ients received irinotecan in combination with 5-FU/LV, 362 patients received 5-FU/LV alone, and 223 patients received irinotecan alone. (See Table 10 in DOSAGE AND ADMINISTRATION for recommended combination-agent regimens.)

In Study 1, 49 (7.3%) patients died within 30 days of last study treatment: 21 (9.3%)

received irinotecan in combination with 5-FU/LV, 15 (6.8%) received 5-FU/LV alone, and 13 (5.8%) received irinotecan alone. Deaths potentially related to treatment occurred in 2 (0.9%) patients who received irinotecan in combination with 5-FU/LV (2 neutropenic fever/sepsis), 3 (1.4%) patients who received 5-FU/LV alone (1 neutropenic fever/sepsis, 1 CNS bleeding during thrombocytopenia, 1 unknown) and 2 (0.9%) patients who received irinotecan alone (2 neutropenic fever). Deaths from any cause within 60 days of first study treatment were reported for 15 (6.7%) patients who received irinotecan in combination with 5-FU/LV, 16 (7.3%) patients who received 5-FU/LV alone, and 15 (6.7%) patients who received irinotecan alone. Discontinuations due to adverse events were reported for 17 (7.6%) patients who received irinotecan in combination with 5FU/LV, 14 (6.4%) patients who received 5-FU/LV alone, and 26 (11.7%) patients who received irinotecan alone.

In Study 2, 10 (3.5%) patients died within 30 days of last study treatment: 6 (4.1%) received irinotecan in combination with 5-FU/LV and 4 (2.8%) received 5-FU/LV alone. There was one potentially treatment-related death, which occurred in a patient who received irinotecan in combination with 5-FU/LV (0.7%, neutropenic sepsis). Deaths from any cause within 60 days of first study treatment were reported for 3 (2.1%) patients who received irinotecan in combination with 5-FU/LV and 2 (1.4%) patients who received 5-FU/LV alone. Discontinuations due to adverse events were reported for 9 (6.2%) patients who received irinotecan in combination with 5FU/LV and 1 (0.7%) patient who received 5-FU/LV alone.

The most clinically significant adverse events for patients receiving irinotecan-based therapy were diarrhea, nausea, vomiting, neutropenia, and alopecia. The most clinically

Page 38: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

significant adverse events for patients receiving 5-FU/LV therapy were diarrhea, neutropenia, neutropenic fever, and mucositis. In Study 1, grade 4 neutropenia, neutropenic fever (defined as grade 2 fever and grade 4 neutropenia), and mucositis were observed less often with weekly irinotecan/5-FU/LV than with monthly administration of 5-FU/LV.

Tables 6 and 7 list the clinically relevant adverse events reported in Studies 1 and 2, respectively.

Page 39: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Table 6. Study 1: Percent (%) of Patients Experiencing Clinically Relevant

Adverse Events in Combination Therapiesa Study 1

Adverse Event

Irinotecan + Bolus 5-FU/LV

weekly x 4 q 6 weeks

N=225

Bolus 5-FU/LV

daily x 5 q 4 weeks

N=219

Irinotecan weekly x 4 q 6 weeks

N=223 Grade 1-4 Grade 3&4 Grade 1-4 Grade 3&4 Grade 1-4 Grade 3&4 TOTAL Adverse Events 100 53.3 100 45.7 99.6 45.7 GASTROINTESTINAL Diarrhea late grade 3 grade 4 early

84.9 -- --

45.8

22.7 15.1 7.6 4.9

69.4 -- --

31.5

13.2 5.9 7.3 1.4

83.0 -- --

43.0

31.0 18.4 12.6 6.7

Nausea 79.1 15.6 67.6 8.2 81.6 16.1 Abdominal pain 63.1 14.6 50.2 11.5 67.7 13.0 Vomiting 60.4 9.7 46.1 4.1 62.8 12.1 Anorexia 34.2 5.8 42.0 3.7 43.9 7.2 Constipation 41.3 3.1 31.5 1.8 32.3 0.4 Mucositis 32.4 2.2 76.3 16.9 29.6 2.2 HEMATOLOGIC Neutropenia grade 3 grade 4

96.9

-- --

53.8 29.8 24.0

98.6

-- --

66.7 23.7 42.5

96.4

-- --

31.4 19.3 12.1

Leukopenia 96.9 37.8 98.6 23.3 96.4 21.5 Anemia 96.9 8.4 98.6 5.5 96.9 4.5 Neutropenic fever -- 7.1 -- 14.6 -- 5.8 Thrombocytopenia 96.0 2.6 98.6 2.7 96.0 1.7 Neutropenic infection -- 1.8 -- 0 -- 2.2 BODY AS A WHOLE Asthenia

70.2

19.5

64.4

11.9

69.1

13.9

Pain 30.7 3.1 26.9 3.6 22.9 2.2 Fever 42.2 1.7 32.4 3.6 43.5 0.4 Infection 22.2 0 16.0 1.4 13.9 0.4 METABOLIC & NUTRITIONAL ↑ Bilirubin

87.6

7.1

92.2

8.2

83.9

7.2 DERMATOLOGIC Exfoliative dermatitis Rash Alopeciab

0.9

19.1 43.1

0 0 --

3.2

26.5 26.5

0.5 0.9 --

0

14.3 46.1

0

0.4 --

RESPIRATORY Dyspnea Cough Pneumonia

27.6 26.7 6.2

6.3 1.3 2.7

16.0 18.3 1.4

0.5 0

1.0

22.0 20.2 3.6

2.2 0.4 1.3

NEUROLOGIC Dizziness Somnolence Confusion

23.1 12.4 7.1

1.3 1.8 1.8

16.4 4.6 4.1

0

1.8 0

21.1 9.4 2.7

1.8 1.3 0

CARDIOVASCULAR Vasodilatation Hypotension Thromboembolic eventsc

9.3 5.8 9.3

0.9 1.3 --

5.0 2.3

11.4

0

0.5 --

9.0 5.8 5.4

0

1.7 --

aSeverity of adverse events based on NCI CTC (version 1.0) bComplete hair loss = Grade 2 c Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder.

Page 40: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Table 7. Study 2: Percent (%) of Patients Experiencing Clinically Relevant

Adverse Events in Combination Therapiesa

Study 2 Adverse Event

Irinotecan + 5-FU/LV

infusional d 1&2 q 2 weeks

N= 145

5-FU/LV

infusional d 1&2 q 2 weeks

N=143 Grade 1-4 Grade 3&4 Grade 1-4 Grade 3&4 TOTAL Adverse Events 100 72.4 100 39.2 GASTROINTESTINAL Diarrhea late grade 3 grade 4 Cholinergic syndromeb

72.4 -- --

28.3

14.4 10.3 4.1 1.4

44.8 -- --

0.7

6.3 4.2 2.1 0

Nausea 66.9 2.1 55.2 3.5 Abdominal pain 17.2 2.1 16.8 0.7 Vomiting 44.8 3.5 32.2 2.8 Anorexia 35.2 2.1 18.9 0.7 Constipation 30.3 0.7 25.2 1.4 Mucositis 40.0 4.1 28.7 2.8 HEMATOLOGIC Neutropenia grade 3 grade 4

82.5

-- --

46.2 36.4 9.8

47.9

-- --

13.4 12.7 0.7

Leukopenia 81.3 17.4 42.0 3.5 Anemia 97.2 2.1 90.9 2.1 Neutropenic fever -- 3.4 -- 0.7 Thrombocytopenia 32.6 0 32.2 0 Neutropenic infection -- 2.1 -- 0 BODY AS A WHOLE Asthenia

57.9

9.0

48.3

4.2

Pain 64.1 9.7 61.5 8.4 Fever 22.1 0.7 25.9 0.7 Infection 35.9 7.6 33.6 3.5 METABOLIC & NUTRITIONAL ↑ Bilirubin

19.1

3.5

35.9

10.6

DERMATOLOGIC Hand & foot syndrome Cutaneous signs Alopeciac

10.3 17.2 56.6

0.7 0.7 --

12.6 20.3 16.8

0.7 0 --

RESPIRATORY Dyspnea

9.7

1.4

4.9

0

CARDIOVASCULAR Hypotension Thromboembolic eventsd

3.4

11.7

1.4 --

0.7 5.6

0 --

a Severity of adverse events based on NCI CTC (version 1.0) b Includes rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, abdominal cramping or diarrhea (occurring during or shortly after infusion of irinotecan) c Complete hair loss = Grade 2 d Includes angina pectoris, arterial thrombosis, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, embolus lower extremity, heart arrest, myocardial infarct, myocardial ischemia, peripheral vascular disorder, pulmonary embolus, sudden death, thrombophlebitis, thrombosis, vascular disorder.

Page 41: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Second-Line Single-Agent Therapy Weekly Dosage Schedule

In three clinical studies evaluating the weekly dosage schedule, 304 patients with metastatic carcinoma of the colon or rectum that had recurred or progressed following 5-FU-based therapy were treated with CAMPTOSAR. Seventeen of the patients died within 30 days of the administration of CAMPTOSAR; in five cases (1.6%, 5/304), the deaths were potentially drug-related. These five patients experienced a constellation of medical events that included known effects of CAMPTOSAR. One of these patients died of neutropenic sepsis without fever. Neutropenic fever occurred in nine (3.0%) other patients; these patients recovered with supportive care.

One hundred nineteen (39.1%) of the 304 patients were hospitalized a total of 156 times because of adverse events; 81 (26.6%) patients were hospitalized for events judged to be related to administration of CAMPTOSAR. The primary reasons for drug-related hospitalization were diarrhea, with or without nausea and/or vomiting (18.4%); neutropenia/leukopenia, with or without diarrhea and/or fever (8.2%); and nausea and/or vomiting (4.9%).

Adjustments in the dose of CAMPTOSAR were made during the cycle of treatment and for subsequent cycles based on individual patient tolerance. The first dose of at least one cycle of CAMPTOSAR was reduced for 67% of patients who began the studies at the 125-mg/m2 starting dose. Within-cycle dose reductions were required for 32% of the cycles initiated at the 125-mg/m2 dose level. The most common reasons for dose reduction were late diarrhea, neutropenia, and leukopenia. Thirteen (4.3%) patients discontinued treatment with CAMPTOSAR because of adverse events. The adverse events in Table 8 are based on the experience of the 304 patients enrolled in the three studies described in the CLINICAL STUDIES, Studies Evaluating the Weekly Dosage Schedule, section.

Page 42: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Table 8. Adverse Events Occurring in >10% of 304 Previously Treated Patients with

Metastatic Carcinoma of the Colon or Rectuma

% of Patients Reporting Body System & Event NCI Grades 1-4 NCI Grades 3 & 4 GASTROINTESTINAL

Diarrhea (late)b 88 31 7-9 stools/day (grade 3) (16) ≥10 stools/day (grade 4) (14) Nausea 86 17 Vomiting 67 12 Anorexia 55 6 Diarrhea (early)c 51 8 Constipation 30 2 Flatulence 12 0 Stomatitis 12 1 Dyspepsia 10 0

HEMATOLOGIC Leukopenia 63 28 Anemia 60 7 Neutropenia 54 26 500 to <1000/mm3 (grade 3) (15) <500/mm3 (grade 4) (12)

BODY AS A WHOLE Asthenia 76 12 Abdominal cramping/pain 57 16 Fever 45 1 Pain 24 2 Headache 17 1 Back pain 14 2 Chills 14 0 Minor infectiond 14 0 Edema 10 1 Abdominal enlargement 10 0

METABOLIC & NUTRITIONAL ↓ Body weight 30 1 Dehydration 15 4 ↑ Alkaline phosphatase 13 4 ↑ SGOT 10 1

DERMATOLOGIC Alopecia 60 NAe

Sweating 16 0 Rash 13 1

RESPIRATORY Dyspnea 22 4 ↑ Coughing 17 0 Rhinitis 16 0

NEUROLOGIC Insomnia 19 0 Dizziness 15 0

CARDIOVASCULAR Vasodilation (flushing) 11 0

a Severity of adverse events based on NCI CTC (version 1.0)

b Occurring > 24 hours after administration of CAMPTOSAR c Occurring ≤24 hours after administration of CAMPTOSAR d Primarily upper respiratory infections e Not applicable; complete hair loss = NCI grade 2

Page 43: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Once-Every-3-Week Dosage Schedule

A total of 535 patients with metastatic colorectal cancer whose disease had recurred or progressed following prior 5-FU therapy participated in the two phase 3 studies: 316 received irinotecan, 129 received 5-FU, and 90 received best supportive care. Eleven (3.5%) patients treated with irinotecan died within 30 days of treatment. In three cases (1%, 3/316), the deaths were potentially related to irinotecan treatment and were attributed to neutropenic infection, grade 4 diarrhea, and asthenia, respectively. One (0.8%, 1/129) patient treated with 5-FU died within 30 days of treatment; this death was attributed to grade 4 diarrhea.

Hospitalizations due to serious adverse events (whether or not related to study treatment) occurred at least once in 60% (188/316) of patients who received irinotecan, 63% (57/90) who received best supportive care, and 39% (50/129) who received 5-FU-based therapy. Eight percent of patients treated with irinotecan and 7% treated with 5-FU-based therapy discontinued treatment due to adverse events.

Of the 316 patients treated with irinotecan, the most clinically significant adverse events (all grades, 1-4) were diarrhea (84%), alopecia (72%), nausea (70%), vomiting (62%), cholinergic symptoms (47%), and neutropenia (30%). Table 9 lists the grade 3 and 4 adverse events reported in the patients enrolled to all treatment arms of the two studies described in the CLINICAL STUDIES, Studies Evaluating the Once-Every-3-Week Dosage Schedule, section.

Page 44: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Table 9. Percent Of Patients Experiencing Grade 3 & 4 Adverse Events

In Comparative Studies Of Once-Every-3-Week Irinotecan Therapya

Study 1 Study 2 Adverse Event

Irinotecan N=189

BSC b

N=90 Irinotecan

N=127 5-FU

N=129 TOTAL Grade 3/4 Adverse Events

79

67

69

54

GASTROINTESTINAL Diarrhea 22 6 22 11 Vomiting 14 8 14 5 Nausea 14 3 11 4 Abdominal pain 14 16 9 8 Constipation 10 8 8 6 Anorexia 5 7 6 4 Mucositis 2 1 2 5 HEMATOLOGIC Leukopenia/Neutropenia 22 0 14 2 Anemia 7 6 6 3 Hemorrhage 5 3 1 3 Thrombocytopenia 1 0 4 2 Infection without grade 3/4 neutropenia 8 3 1 4 with grade 3/4 neutropenia 1 0 2 0 Fever without grade 3/4 neutropenia 2 1 2 0 with grade 3/4 neutropenia 2 0 4 2 BODY AS A WHOLE Pain 19 22 17 13 Asthenia 15 19 13 12 METABOLIC & NUTRITIONAL

Hepatic c 9 7 9 6 DERMATOLOGIC Hand & foot syndrome 0 0 0 5 Cutaneous signs d 2 0 1 3 RESPIRATORY e 10 8 5 7 NEUROLOGIC f 12 13 9 4 CARDIOVASCULAR g 9 3 4 2 OTHER h 32 28 12 14 a Severity of adverse events based on NCI CTC (version 1.0) b BSC = best supportive care c Hepatic includes events such as ascites and jaundice d Cutaneous signs include events such as rash e Respiratory includes events such as dyspnea and cough f Neurologic includes events such as somnolence g Cardiovascular includes events such as dysrhythmias, ischemia, and mechanical cardiac dysfunction h Other includes events such as accidental injury, hepatomegaly, syncope, vertigo, and weight loss Overview of Adverse Events Gastrointestinal: Nausea, vomiting, and diarrhea are common adverse events following treatment with CAMPTOSAR and can be severe. When observed, nausea and vomiting usually occur during or shortly after infusion of CAMPTOSAR. In the clinical studies testing the every 3-week-dosage schedule, the median time to the onset of late diarrhea was 5 days after irinotecan infusion. In the clinical studies evaluating the weekly dosage schedule, the median time to onset of late diarrhea was 11 days following administration of CAMPTOSAR. For patients starting treatment at the 125-mg/m2 weekly dose, the median duration of any grade of late diarrhea was 3 days. Among those

Page 45: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

patients treated at the 125-mg/m2 weekly dose who experienced grade 3 or 4 late diarrhea, the median duration of the entire episode of diarrhea was 7 days. The frequency of grade 3 or 4 late diarrhea was somewhat greater in patients starting treatment at 125 mg/m2 than in patients given a 100-mg/m2 weekly starting dose (34% [65/193] versus 23% [24/102]; p=0.08). The frequency of grade 3 and 4 late diarrhea by age was significantly greater in patients ≥65 years than in patients <65 years (40% [53/133] versus 23% [40/171]; p=0.002). In one study of the weekly dosage treatment, the frequency of grade 3 and 4 late diarrhea was significantly greater in male than in female patients (43% [25/58] versus 16% [5/32]; p=0.01), but there were no gender differences in the frequency of grade 3 and 4 late diarrhea in the other two studies of the weekly dosage treatment schedule. Colonic ulceration, sometimes with gastrointestinal bleeding, has been observed in association with administration of CAMPTOSAR. Hematology: CAMPTOSAR commonly causes neutropenia, leukopenia (including lymphocytopenia), and anemia. Serious thrombocytopenia is uncommon. When evaluated in the trials of weekly administration, the frequency of grade 3 and 4 neutropenia was significantly higher in patients who received previous pelvic/abdominal irradiation than in those who had not received such irradiation (48% [13/27] versus 24% [67/277]; p=0.04). In these same studies, patients with baseline serum total bilirubin levels of 1.0 mg/dL or more also had a significantly greater likelihood of experiencing first-cycle grade 3 or 4 neutropenia than those with bilirubin levels that were less than 1.0 mg/dL (50% [19/38] versus 18% [47/266]; p<0.001). There were no significant differences in the frequency of grade 3 and 4 neutropenia by age or gender. In the clinical studies evaluating the weekly dosage schedule, neutropenic fever (concurrent NCI grade 4 neutropenia and fever of grade 2 or greater) occurred in 3% of the patients; 6% of patients received G-CSF for the treatment of neutropenia. NCI grade 3 or 4 anemia was noted in 7% of the patients receiving weekly treatment; blood transfusions were given to 10% of the patients in these trials. Body as a Whole: Asthenia, fever, and abdominal pain are generally the most common events of this type. Cholinergic Symptoms: Patients may have cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping and early diarrhea. If these symptoms occur, they manifest during or shortly after drug infusion. They are thought to be related to the anticholinesterase activity of the irinotecan parent compound and are expected to occur more frequently with higher irinotecan doses. Hepatic: In the clinical studies evaluating the weekly dosage schedule, NCI grade 3 or 4 liver enzyme abnormalities were observed in fewer than 10% of patients. These events typically occur in patients with known hepatic metastases. Dermatologic: Alopecia has been reported during treatment with CAMPTOSAR. Rashes have also been reported but did not result in discontinuation of treatment. Respiratory: Severe pulmonary events are infrequent. In the clinical studies evaluating the weekly dosage schedule, NCI grade 3 or 4 dyspnea was reported in

Page 46: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

4% of patients. Over half the patients with dyspnea had lung metastases; the extent to which malignant pulmonary involvement or other preexisting lung disease may have contributed to dyspnea in these patients is unknown.

Interstitial pulmonary disease presenting as pulmonary infiltrates is uncommon during irinotecan therapy. Interstitial pulmonary disease can be fatal. Risk factors possibly associated with the development of interstitial pulmonary disease include pre-existing lung disease, use of pneumotoxic drugs, radiation therapy, and colony stimulating factors. Patients with risk factors should be closely monitored for respiratory symptoms before and during irinotecan therapy. Neurologic: Insomnia and dizziness can occur, but are not usually considered to be directly related to the administration of CAMPTOSAR. Dizziness may sometimes represent symptomatic evidence of orthostatic hypotension in patients with dehydration. Cardiovascular: Vasodilation (flushing) may occur during administration of CAMPTOSAR. Bradycardia may also occur, but has not required intervention. These effects have been attributed to the cholinergic syndrome sometimes observed during or shortly after infusion of CAMPTOSAR. Thromboembolic events have been observed in patients receiving CAMPTOSAR; the specific cause of these events has not been determined. Other Non-U.S. Clinical Trials

Irinotecan has been studied in over 1100 patients in Japan. Patients in these studies had a variety of tumor types, including cancer of the colon or rectum, and were treated with several different doses and schedules. In general, the types of toxicities observed were similar to those seen in U.S. trials with CAMPTOSAR. There is some information from Japanese trials that patients with considerable ascites or pleural effusions were at increased risk for neutropenia or diarrhea. A potentially life-threatening pulmonary syndrome, consisting of dyspnea, fever, and a reticulonodular pattern on chest x-ray, was observed in a small percentage of patients in early Japanese studies. The contribution of irinotecan to these preliminary events was difficult to assess because these patients also had lung tumors and some had preexisting nonmalignant pulmonary disease. As a result of these observations, however, clinical studies in the United States have enrolled few patients with compromised pulmonary function, significant ascites, or pleural effusions. Post-Marketing Experience

The following events have been identified during postmarketing use of CAMPTOSAR in clinical practice. Myocardial ischemic events have been observed following irinotecan therapy predominantly in patients with underlying cardiac disease, other known risk factors for cardiac disease or previous cytotoxic chemotherapy (See also Table 7, thromboembolic events). Infrequent cases of ulcerative and ischemic colitis have been observed. This can be complicated by ulceration, bleeding, ileus, obstruction, and infection, including typhlitis. Patients experiencing ileus should receive prompt antibiotic support (see PRECAUTIONS). Rare cases of megacolon and intestinal perforation have been reported. Rare cases of symptomatic pancreatitis or asymptomatic elevated pancreatic enzymes have been observed.

Hypersensitivity reactions including severe anaphylactic or anaphylactoid

Page 47: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

reactions have also been observed (see WARNINGS). Rare cases of hyponatremia mostly related with diarrhea and vomiting have been

reported. Increases in serum levels of transaminases (i.e., AST and ALT) in the absence of progressive liver metastasis; transient increase of amylase and occasionally transient increase of lipase have been very rarely reported.

Infrequent cases of renal insufficiency including acute renal failure, hypotension or circulatory failure have been observed in patients who experienced episodes of dehydration associated with diarrhea and/or vomiting, or sepsis (see WARNINGS).

Early effects such as muscular contraction or cramps and paresthesia have been reported.

Hiccups have been reported. OVERDOSAGE

In U.S. phase 1 trials, single doses of up to 345 mg/m2 of irinotecan were administered to patients with various cancers. Single doses of up to 750 mg/m2 of irinotecan have been given in non-U.S. trials. The adverse events in these patients were similar to those reported with the recommended dosage and regimen. There have been reports of overdosage at doses up to approximately twice the recommended therapeutic dose, which may be fatal. The most significant adverse reactions reported were severe neutropenia and severe diarrhea. There is no known antidote for overdosage of CAMPTOSAR. Maximum supportive care should be instituted to prevent dehydration due to diarrhea and to treat any infectious complications.

DOSAGE AND ADMINISTRATION Dosage in Patients with Reduced UGT1A1 Activity When administered in combination with other agents, or as a single-agent, a reduction in the starting dose by at least one level of CAMPTOSAR should be considered for patients known to be homozygous for the UGT1A1*28 allele (see CLINICAL PHARMACOLOGY and WARNINGS). However, the precise dose reduction in this patient population is not known and subsequent dose modifications should be considered based on individual patient tolerance to treatment (see Tables 10-13). Combination-Agent Dosage Dosage Regimens CAMPTOSAR Injection in Combination with 5-Fluorouracil (5-FU) and Leucovorin (LV)

C A M P T O S A R s h o u l d b e a d m i n i s t e r e d a s a n i n t r a v e n o u s infusion over 90 minutes (see Preparation of Infusion Solution). For all regimens, the dose of LV should be administered immediately after CAMPTOSAR, with the a d m i n i s t r a t i o n o f 5 - F U t o o c c u r i m m e d i a t e l y a f t e r r e c e i p t o f LV . C A M P T O S A R s h o u l d b e u s e d a s r e c o m m e n d e d ; t h e c u r r e n t l y r e c o m m e n d e d r e g i m e n s a r e s h o w n i n T a b l e 1 0 .

Table 10. Combination-Agent Dosage Regimens & Dose Modificationsa

125 mg/m2 IV over 90 min, d 1,8,15,22 20 mg/m2 IV bolus, d 1,8,15,22 500 mg/m2 IV bolus, d 1,8,15,22 Starting Dose & Modified Dose Levels (mg/m2)

Regimen 1 6-wk cycle with bolus 5-FU/LV (next cycle begins on day 43)

CAMPTOSAR LV 5-FU

Starting Dose Dose Level -1 Dose Level -2

Page 48: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

CAMPTOSAR 125 100 75

LV 20 20 20

5-FU 500 400 300

Regimen 2 6-wk cycle with infusional 5-FU/LV (next cycle begins on day 43)

CAMPTOSAR LV 5-FU Bolus 5-FU Infusionb

180 mg/m2 IV over 90 min, d 1,15,29 200 mg/m2 IV over 2 h, d 1,2,15,16,29,30 400 mg/m2 IV bolus, d 1,2,15,16,29,30 600 mg/m2 IV over 22 h, d 1,2,15,16,29,30

Starting Dose & Modified Dose Levels (mg/m2)

Starting Dose Dose Level -1 Dose Level -2

CAMPTOSAR 180 150 120

LV 200 200 200

5-FU Bolus 5-FU Infusionb

400 600

320 480

240 360

aDose reductions beyond dose level –2 by decrements of ≈20% may be warranted for patients continuing to experience toxicity. Provided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit. bInfusion follows bolus administration.

Dosing for patients with bilirubin >2 mg/dL cannot be recommended be c a u s e t h e r e

i s i n s u f f i c i e n t i n f o r m a t i o n t o r e c o m m e n d a d o s e i n t h e s e p a t i e n t s . I t i s r e c o m m e n d e d t h a t p a t i e n t s r e c e i v e premedication with antiemetic agents. Prophylactic or t h e r a p e u t i c a d m i n i s t r a t i o n o f a t r o p i n e sh o u l d b e c o n s i d e r e d i n p a t i e n t s e x p e r i e n c i n g c h o l i n e r g i c s ym p t o m s . S e e PRECAUTIONS, General.

Dose Modifications Patients should be carefully monitored for toxicity and assessed prior to each treatment.

Doses of CAMPTOSAR and 5-FU should be modified as necessary to accommod a t e i n d i v i d u a l p a t i e n t t o l e r a n c e t o t r e a t m e n t . Ba s e d o n the recommended dose-levels described in Table 10, C o m b i n a t i o n - A ge n t D o s a ge R e g i m e n s & D o s e M o d i f i c a t i o n s , s u b s e q u e n t d o s e s s h o u l d b e a d j u s t e d a s s u gge s t e d in Table 11, Recommended Dose Modifications for C o m b i n a t i o n S c h e d u l e s . A l l d o s e m o d i f i c a t i o n s s h o u l d b e based on the worst preceding toxicity. After the first t r e a t m e n t , p a t i e n t s w i t h a c t i v e d i a r r h e a s h o u l d r e t u r n t o pre-treatment bowel function without requiring anti-diarrhea medications for at least 24 hours before the n e x t c h e m o t h e r a p y a d m i n i s t r a t i o n .

A n e w c yc l e o f t h e r a p y s h o u l d n o t b e g i n u n t i l t h e t o x i c i t y h a s r e c o v e r e d t o N C I g r a d e 1 o r l e s s . T r e a t m e n t m a yb e d e l a ye d 1 t o 2 w e e k s t o a l l o w f o r r e c o v e r y f r o m t r e a t ment-related tox ici ty. If the pat ient has not recovered, c o n s i d e r a t i o n s h o u l d b e g i v e n t o d i s c o n t i n u i n g t h e r a p y. P r o v i d e d i n t o l e r a b l e t o x i c i t y d o e s n o t d e v e l o p , t r e a t m e n t with additional cycles of CAMPTOSAR/5-FU/LV may be continued indefinitely as long as patients continue to e x p e r i e n c e c l i n i c a l b e n e f i t .

Page 49: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Table 11. Recommended Dose Modifications for CAMPTOSAR/5-Fluorouracil (5-FU)/Leucovorin (LV) Combination Schedules

Patients should return to pre-treatment bowel function without requiring antidiarrhea medications for at least 24 hours before the next chemotherapy administration. A new cycle of therapy should not begin until the granulocyte count has recovered to ≥1500/mm3, and the platelet count has recovered to ≥100,000/mm3, and treatment-related diarrhea is fully resolved. Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consideration should be given to discontinuing therapy

Toxicity NCI CTC Gradea (Value)

During a Cycle of Therapy At the Start of Subsequent Cycles of Therapyb

No toxicity Maintain dose level Maintain dose level Neutropenia 1 (1500 to 1999/mm3) 2 (1000 to 1499/mm3) 3 (500 to 999/mm3) 4 (<500/mm3)

Maintain dose level ↓ 1 dose level Omit dose until resolved to ≤ grade 2, then ↓ 1 dose level Omit dose until resolved to ≤ grade 2, then ↓ 2 dose levels

Maintain dose level Maintain dose level ↓ 1 dose level ↓ 2 dose levels

Neutropenic fever Omit dose until resolved, then ↓ 2 dose levels Other hematologic toxicities Dose modifications for leukopenia or thrombocytopenia during a cycle of therapy and at the start of

subsequent cycles of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.

Diarrhea 1 (2-3 stools/day > pretxc) 2 (4-6 stools/day > pretx) 3 (7-9 stools/day > pretx) 4 (≥10 stools/day > pretx)

Delay dose until resolved to baseline, then give same dose Omit dose until resolved to baseline, then ↓ 1 dose level Omit dose until resolved to baseline, then ↓ 1 dose level Omit dose until resolved to baseline, then ↓ 2 dose levels

Maintain dose level Maintain dose level ↓ 1 dose level ↓ 2 dose levels

Other nonhematologic toxicitiesd

1 2 3 4

Maintain dose level Omit dose until resolved to ≤ grade 1, then ↓ 1 dose level Omit dose until resolved to ≤ grade 2, then ↓ 1 dose level Omit dose until resolved to ≤ grade 2, then ↓ 2 dose levels For mucositis/stomatitis decrease only 5-FU, not CAMPTOSAR

Maintain dose level Maintain dose level ↓ 1 dose level ↓ 2 dose levels For mucositis/stomatitis decrease only 5-FU, not CAMPTOSAR.

a National Cancer Institute Common Toxicity Criteria (version 1.0) b Relative to the starting dose used in the previous cycle c Pretreatment d Excludes alopecia, anorexia, asthenia

Single-Agent Dosage Schedules Dosage Regimens

CAMPTOSAR should be adminis te red as an in t ravenous i n f u s i o n o v e r 9 0 m i n u t e s f o r b o t h t h e w e e k l y a n d o n c e - every-3-week dosage schedules (see Preparation of Infusion Solution). Single-agent dosage regimens are s h o w n i n T a b l e 1 2 .

Table 12. Single-Agent Regimens of CAMPTOSAR and Dose Modifications

Weekly Regimena 125 mg/m2 IV over 90 min, d 1,8,15,22 then 2-wk rest Starting Dose & Modified Dose Levelsc (mg/m2)

Starting Dose Dose Level -1 Dose Level -2

125 100 75

Once-Every-3-Week Regimenb 350 mg/m2 IV over 90 min, once every 3 wksc

Starting Dose & Modified Dose Levels (mg/m2)

Starting Dose Dose Level -1 Dose Level -2

350 300 250

Page 50: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

aSubsequent doses may be adjusted as high as 150 mg/m2 or to as low as 50 mg/m2 in 25 to 50 mg/m2 decrements depending upon individual patient tolerance. bSubsequent doses may be adjusted as low as 200 mg/m2 in 50 mg/m2 decrements depending upon individual patient tolerance. cProvided intolerable toxicity does not develop, treatment with additional cycles may be continued indefinitely as long as patients continue to experience clinical benefit.

A reduction in the starting dose by one dose level of CAMPTOSAR may be

cons idered for pa t ien t s wi th any of the following conditions: age ≥65 years, prior pelvic/abdominal radiotherapy, performance status of 2, or increased bi l i rubin levels . Dosing for pat ients wi th bilirubin >2 mg/dL cannot be recommended because there is insufficient information to recommend a dose in these patients.

It is recommended that patients receive premedication with antiemetic agents.

Prophylactic or therapeutic administration of atropine should be considered in pat ients experiencing chol inergic symptoms. See PRECAUTIONS, General. Dose Modifications

Patients should be carefully monitored for toxicity and doses of CAMPTOSAR should be modified as necessary to accommodate individual pat ient to lerance to t reatment . Based on recommended dose- levels descr ibed in Table 12, Single-Agent Regimens of CAMPTOSAR and Dose Modifications, subsequent doses should be adjusted as suggested in Table 13, Recommended Dose Modifications for Single-Agent Schedules. All dose modifications should be based on the worst preceding toxicity.

A new cycle of therapy should not begin until the toxicity has recovered to NCI grade 1 or less. Treatment may be delayed 1 to 2 weeks to allow for recovery from treatment-related tox ici ty. If the pat ient has not recovered, consideration should be given to discontinuing this combination therapy. Provided intolerable toxicity does not develop, treatment with additional cycles of CAMPTOSAR may be continued indefinitely as long as patients continue to experience clinical benefit.

Page 51: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Table 13. Recommended Dose Modifications For Single-Agent Schedulesa

A new cycle of therapy should not begin until the granulocyte count has recovered to ≥1500/mm3, and the platelet count has recovered to ≥100,000/mm3, and treatment-related diarrhea is fully resolved. Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consideration should be given to discontinuing CAMPTOSAR.

Worst Toxicity

NCI Gradeb (Value)

During a Cycle of Therapy

At the Start of the Next Cycles of Therapy (After Adequate Recovery), Compared with

the Starting Dose in the Previous Cyclea

Weekly Weekly Once Every 3 Weeks No toxicity Maintain dose level ↑ 25 mg/m2 up to a

maximum dose of 150 mg/m2

Maintain dose level

Neutropenia 1 (1500 to 1999/mm3) 2 (1000 to 1499/mm3) 3 (500 to 999/mm3) 4 (<500/mm3)

Maintain dose level ↓ 25 mg/m2 Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m2

Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m2

Maintain dose level Maintain dose level ↓ 25 mg/m2

↓ 50 mg/m2

Maintain dose level Maintain dose level ↓ 50 mg/m2

↓ 50 mg/m2

Neutropenic fever Omit dose until resolved, then ↓ 50 mg/m2 when resolved ↓ 50 mg/m2 ↓ 50 mg/m2

Other hematologic toxicities

Dose modifications for leukopenia, thrombocytopenia, and anemia during a cycle of therapy and at the start of subsequent cycles of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.

Diarrhea 1 (2-3 stools/day > pretxc) 2 (4-6 stools/day > pretx) 3 (7-9 stools/day > pretx) 4 (≥10 stools/day > pretx)

Maintain dose level ↓ 25 mg/m2 Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m2

Omit dose until resolved to ≤ grade 2 then ↓ 50 mg/m2

Maintain dose level Maintain dose level ↓ 25 mg/m2

↓ 50 mg/m2

Maintain dose level Maintain dose level ↓ 50 mg/m2

↓ 50 mg/m2

Other nonhematologicd toxicities 1 2 3 4

Maintain dose level ↓ 25 mg/m2 Omit dose until resolved to ≤ grade 2, then ↓ 25 mg/m2

Omit dose until resolved to ≤ grade 2, then ↓ 50 mg/m2

Maintain dose level ↓ 25 mg/m2

↓ 25 mg/m2

↓ 50 mg/m2

Maintain dose level ↓ 50 mg/m2

↓ 50 mg/m2

↓ 50 mg/m2

a All dose modifications should be based on the worst preceding toxicity b National Cancer Institute Common Toxicity Criteria (version 1.0) c Pretreatment d Excludes alopecia, anorexia, asthenia

Preparation & Administration Precautions

As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions prepared from CAMPTOSAR Injection. The use of gloves is recommended. If a solution of CAMPTOSAR contacts the skin, wash the skin immediately and thoroughly with soap and water . If CAMPTOSAR contacts the mucous membranes, flush thoroughly with water. Several published guidelines for handling and disposal of anticancer agents are available.1-7 Preparation of Infusion Solution

Inspect vial contents for particulate matter and repeat inspection when drug product is withdrawn from vial into syringe.

CAMPTOSAR Injection must be diluted prior to infusion. CAMPTOSAR should be diluted in 5% Dextrose Injection, USP, (preferred) or 0.9% Sodium Chloride Injection, USP, to a final concentration range of 0.12 to 2.8 mg/mL. In most clinical trials, CAMPTOSAR was administered in 250 mL to 500 mL o f 5% Dex t rose In j ec t ion , USP .

The so lu t i on i s phys i ca l l y and chemica l ly s t ab l e fo r up to 24 hours at room temperature (approximately 25°C) and i n ambien t f l uo rescen t l i gh t ing . So lu t ions d i l u t ed i n 5% Dextrose Injection, USP, and stored at refrigerated temperatures (approximately 2° to 8°C), and protected from light are physically and chemically stable for 48 hours. Refrigeration of admixtures using 0.9% Sodium Ch lo r ide In j ec t ion , USP , i s no t r ecommended due to a l ow and sporadic

Page 52: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

incidence of visible particulates. Freezing CAMPTOSAR and admixtures of CAMPTOSAR may result in p rec ip i t a t ion o f t he d rug and shou ld be avo ided . Because o f poss ib l e mic rob ia l con tamina t ion du r ing d i l u t i on , i t i s advisable to use the admixture prepared with 5%Dextrose Injection, USP, within 24 hours if refrigerated (2° to 8°C, 36° to 46°F). In the case of admixtures prepared with 5% Dextrose Injection, USP, or Sodium Chloride Injection, USP, the solutions should be used within 6 hours if kept at room temperature (15° to 30°C, 59° t o 86°F) .

Other drugs should not be added to the infusion solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. HOW SUPPLIED

Each mL of CAMPTOSAR Injection contains 20 mg irinotecan (on the basis of the trihydrate salt); 45 mg sorbitol; and 0.9 mg lactic acid. When necessary, pH has been adjusted to 3.5 (range, 3.0 to 3.8) with sodium hydroxide or hydrochloric acid.

CAMPTOSAR Injection is available in single-dose amber glass vials in the following package sizes: 2 mL NDC 0009-7529-02 5 mL NDC 0009-7529-01

The vial should be inspected for damage and visible signs of leaks before

removing from the carton. If damaged, incinerate the unopened package. Store at controlled room temperature 15° to 30°C (59° to 86°F). Protect from

light. It is recommended that the vial should remain in the carton until the time of use. Rx only

REFERENCES 1. ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and

Recommendations for Practice. Pittsburgh, Pa: Oncology Nursing Society; 1999:32-

41.

2. Recommendations for the safe handling of parenteral antineoplastic drugs.

Washington, DC: Division of Safety, National Institutes of Health; 1983. US Dept of

Health and Human Services, Public Health Service publication NIH 83-2621.

3. AMA Council on Scientific Affairs. Guidelines for handling parenteral

antineoplastics. JAMA. 1985;253:1590-1592.

4. National Study Commission on Cytotoxic Exposure. Recommendations for handling

cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman, National Study

Page 53: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied

Health Sciences, 179 Longwood Avenue, Boston, MA 02115.

5. Clinical Oncological Society of Australia. Guidelines and recommendations for safe

handling of antineoplastic agents. Med J Australia. 1983;1:426-428.

6. Jones RB, Frank R, Mass T. Safe handling of chemotherapeutic agents: a report from

the Mount Sinai Medical Center. CA-A Cancer J for Clin. 1983;33:258-263.

7. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on

handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990;47:1033-1049.

8. Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice

Guidelines). Am J Health-SystPharm. 1996;53;1669-1685.

Licensed from Yakult Honsha Co., LTD, Japan, and Daiichi Pharmaceutical Co., LTD, Japan Revised July 2008

LAB-0134-13.0

Page 54: Tailoring treatment for metastatic colorectal cancer · Tailoring treatment for metastatic colorectal cancer: considerations for first-line therapy Key Points • Colorectal cancer

CQ278602A© 2007 Current Medicine Group LLC